

Reactivity of (Z)-4-Aryliden-5(4H)-thiazolones: [2 + 2]-Photocycloaddition, Ring-Opening Reactions, and Influence of the Lewis Acid BF₃

Sonia Sierra, David Dalmau, Sheila Higuera, Darío Cortés, Olga Crespo, Ana I. Jimenez, Alexandra Pop, Cristian Silvestru, and Esteban P. Urriolabeitia*

Cite This: *J. Org. Chem.* 2021, 86, 12119–12140

Read Online


ACCESS |

Metrics & More

Article Recommendations

Supporting Information

ABSTRACT: The irradiation of (Z)-2-phenyl-4-aryliden-5(4H)-thiazolones **2** with blue light (465 nm) in CH₂Cl₂ solution promotes [2 + 2]-photocycloaddition of the exocyclic C=C bonds and the formation of the dispirocyclobutanes **3**. This reaction takes place with high stereoselectivity, given that the ϵ -isomer (1,3 head-to-tail syn coupling) is formed in more than 90% yield in most of the cases. However, irradiation of 5(4H)-thiazolones **2** with blue light (456 nm) in dry MeOH in the presence of BF₃·OEt₂ leads to the monspirocyclobutanes **4** with full stereoselectivity, also affording the ϵ -isomer. A ring-opening reaction of only one of the thiazolone rings appears to have taken place in **4** upon methanolysis, leading to the corresponding ester and thioamide groups. The treatment of free 4-aryliden-5(4H)-thiazolones **2** with a base in alcohol (NaOR/ROH) also produces a ring-opening reaction of the heterocycle by methanolysis, although, under these reaction conditions, further intramolecular S-attack at the exocyclic C(H)=C bond and cyclization is observed, forming the dihydrothiazoles **5** or **6** as mixtures of *cis* (RS/SR)- and *trans* (RR/SS)-isomers with high diastereomeric excess. *trans*-(RR/SS)-Dihydrothiazoles **6** can be isolated as pure diastereoisomers by column chromatography. Surprisingly, dihydrothiazoles **5** can also be obtained by the treatment of 4-aryliden-5(4H)-thiazolones **2** with BF₃·OEt₂ in methanol in the absence of a base.



INTRODUCTION

The [2 + 2]-photocycloaddition reaction is a powerful synthetic tool for the tailored and versatile preparation of cyclobutanes by the C—C coupling of olefinic C=C bonds.¹ The relevance of the cyclobutane ring resides in its presence as a common structural motif in natural products or synthetic compounds with strong pharmacological activity. Some examples of relevant cyclobutanes can be found in Figure 1.^{2–7} Moreover, cyclobutanes are also interesting synthetic intermediates as they show a particular reactivity due to the high ring strain.^{8–11}

Figure 1 also shows that these cyclobutanes contain many chiral centers. The development of methods for control of the stereoselectivity during cyclobutane synthesis has attracted substantial attention.^{12–15} However, for photochemical processes, a high stereoselectivity is only achieved when the reactions take place in the solid state and topochemical Schmidt's conditions are achieved. This is the case, for instance, for the synthesis of α -truxillic (Figure 1b) and β -truxinic acid derivatives.^{16–18} In general, the [2 + 2]-photocycloadditions performed in solution suffer a lack of stereoselectivity, and the use of auxiliary reagents such as chiral templates, sensitizers or catalysts, is mandatory.^{19–31}

We are interested in a particular family of cyclobutanes, namely, 1,3-diaminotruxillic derivatives (Figure 2), which are well-known because of their antinociceptive activity. A renewed interest in these compounds has arisen over the past few years because truxillic derivatives have been shown to be FABP (fatty acid binding protein) inhibitors and are responsible for the cellular reuptake of anandamide (an endocannabinoid neurotransmitter).^{32–36} As a result, they are promising candidates in efficient treatments for chronic pain.³⁷ However, this is not the only outstanding pharmacological activity of truxillic derivatives as they have also been recently shown to be the only nonpeptidic GLP-1R (glucagon-like peptide receptor) agonists for the treatment of type 2 diabetes mellitus.^{38–40}

Received: June 21, 2021

Published: August 16, 2021






Figure 1. Cyclobutanes with important pharmacological activity.




Figure 2. Context of this work, comparison with previous work and main achievements.




Figure 3. Thiazolones 2a–2o used in this work and synthetic method.




Figure 4. [2 + 2]-Photocycloaddition of 4-arylidene-5(4H)-thiazolones 2 to give cyclobutanes 3.

As a result of this interest, we have developed different methodologies for the stereoselective synthesis of 1,3-diaminotruaxillic derivatives (Figure 2). Among these, the direct irradiation of (*Z*)-4-arylidene-5(4*H*)-oxazolones 1 shows high simplicity and versatility, together with some degree of stereoselectivity (Figure 2, past work, path a).⁴¹ Thus, we have shown that the [2 + 2]-photocycloaddition of oxazolones 1 can occur using low-power (less than 20W), blue light (465 nm) irradiation sources. This method works for oxazolones bearing electron-donating and electron-withdrawing substituents and gives quantitative yields of cyclobutanes in almost all cases studied. However, it requires long reaction times (up to 3 days) and affords up to four different stereoisomers, although one of them (ϵ) is obtained in 50–90% abundance with respect to the other isomers. This method has been complemented with another, three-step strategy in which a palladium complex behaves as a template, thus allowing the isolation of 1,3-diaminotruaxillic derivatives with good yields as single isomers (Figure 2, past work, path b).^{42–45}

The (*Z*)-4-arylidene-5(4*H*)-thiazolones 2 are the sulfur counterparts of 4-arylidene-5(4*H*)-oxazolones 1. Despite the structural analogy, unsaturated 5(4*H*)-thiazolones are less well-known, and their synthetic potential is underdeveloped.^{46,47} Sulfur-containing drugs exhibit remarkable pharmacological activity, and as such, they are targets of particular interest from the point of view of pharmaceutical companies.⁴⁸ Proof of this interest is the fact that there are at least 249 sulfur-containing drugs approved by the US Food and Drug Administration (FDA).⁴⁹ Thiazolones have received some attention as sulfur-containing drugs, initially during the study of penicillin (it was believed that the active substance contained a thiazolone ring rather than a thiazolidine),^{50,51} and more recently as promising anticancer compounds.⁵² Due to the close relationship between 5(4*H*)-oxazolones 1 and 5(4*H*)-thiazolones 2, the interesting reactivity of oxazolones to give 1,3-diaminotruaxillic derivatives observed in our previous studies,^{41–45} the interest in sulfur-containing compounds due to their interesting pharmacological properties, and the complete absence of

previous studies in this area, we have studied the reactivity of (*Z*)-4-arylidene-5(4*H*)-thiazolones 2 in [2 + 2]-photocycloaddition reactions and in ring-opening reactions upon alcoholysis (Figure 2, this work). With the aim of further exploring the chemical possibilities of these substrates, and taking into account the known influence of Lewis acids on photochemical reactions^{26,28,53–62} (acceleration and/or change in the orientation and selectivity of the reactions), we have examined both processes (ring opening and photocycloaddition) in the presence of a simple Lewis acid, namely BF₃, and present the results obtained below.

RESULTS AND DISCUSSION

Synthesis of (*Z*)-4-Arylidene-5(4*H*)-thiazolones 2 and [2 + 2]-Photocycloaddition by Direct Irradiation. The thiazolones 2a–2o used in this work are shown in Figure 3. Synthesis was carried out following the same experimental procedure reported by Rao and Filler,⁴⁶ which in turn were based on the original work of Behringer et al.^{63,64} Following this method, the treatment of oxazolones 1a–1o with thioacetic acid in the presence of substoichiometric amounts of NEt₃ gave the corresponding thiazolones 2a–2o as air- and moisture-stable solids. Thiazolones 2a–2o contain electron-withdrawing or electron-donating substituents at different positions of the 4-arylidene ring in order to cover the widest scope. Thiazolones 2a–2c have been described previously, although 2b was prepared using a different method,^{65,66} and although thiazolones 2e, 2f, 2g, 2h, and 2j appear in Scifinder, there are either no references associated with their synthesis or no details can be found in the corresponding literature. As such, they are fully characterized here (see Supporting Information).

The HRMS (ESI⁺) spectra of 2a–2o show peaks in agreement with the stoichiometries proposed in Figure 3. In addition, the ¹H NMR spectra of 2a–2o show a pattern of peaks quite similar to that of the oxazolone precursors 1a–1o, with only the signal due to the *ortho*-H of the 2-Ph ring in 2a–2o showing a downfield shift with respect to the same signal in




Figure 5. Scope of the [2 + 2]-photocycloaddition of thiazolones **2** to give cyclobutanes **3**.

Table 1. Yields of Cyclobutanes **3**, Obtained as Mixtures of Isomers, and Composition of the Mixtures

	3a	3b	3c	3d	3e	3f	3g	3h	3j	3k	3m	3n	3o
yield	82	100	100	100	85	92	100	80 ^a	95	98	100	100	90
ϵ (%)	100	90	59	91	96	83	100	100	71	65	85	91	94
α (%)	0	10	25	9	4	17	0	0	29	35	15	9	6
others (%)			9:7										

^aMaximum conversion achieved.

1a–1o. The ¹³C NMR spectra of **2a–2o**, in which the signal due to the S—C (=O) carbon appears around 195 ppm, downfield shifted by more than 20 ppm with respect to the O—C (=O) carbonyl carbon peak (around 170 ppm), are much more informative.

Solutions of thiazolones **2a–2o** in CH₂Cl₂ were then irradiated with blue light (465 nm) at room temperature using the irradiation setup described in the Experimental Section (PCB with 24 blue LEDs). This irradiation promoted the [2 + 2]-photocycloaddition of the exocyclic C=C bond of thiazolones **2** and formation of the corresponding cyclobutanes **3** (Figure 4), which were isolated as air-stable solids after solvent evaporation and recrystallization from CH₂Cl₂/*n*-pentane.

The optimum reaction time for full conversion of **2** using the PCB, as determined by ¹H NMR monitoring, was 72 h. This

reaction time can be shortened to 24 h if a Kessil lamp (456 nm) is used instead, probably due to the higher photonic flux of the latter. The reaction also takes place in other solvents (for instance, methanol), giving the same yield of cyclobutanes **3**. Identical results were obtained in CH₂Cl₂ in the presence or absence of oxygen. No photocycloaddition was observed for **2i** and **2l**, and partial conversion was obtained for **2h**, despite the photonic flux used. The scope of the reaction (Figure 5) appears to be general as it takes place with full conversions and very good yields of isolated products in the presence of either electron-donating (Me, OMe) or electron-withdrawing (F, Cl, Br, NO₂, CF₃) substituents. A change in position of the substituents (*ortho* vs *para*) in the 4-arylidene ring is well tolerated (compare **3e** with **3j** or **3f** with **3k**), as is the presence of two substituents in the *meta*- and *para*-positions (**3m–3o**).

NMR analysis of the cyclobutanes **3** represented in Figures 4 and 5 showed that they were mainly obtained as single isomers (**3a**, **3g**, **3h**) or as mixtures of two isomers with molar ratios of 80:20 or higher (**3b**, **3d**, **3e**, **3f**, **3m**, **3n**, **3o**; see Table 1 and Experimental Section). Given that the photocycloaddition of thiazolones **2** can afford up to 11 different isomers, the stereoselectivity of the process presented here is remarkable. A comparison of these results with those obtained with related substrates shows that the use of thiazolones results in a more selective process. For instance, we have reported the synthesis of cyclobutanes by direct [2 + 2]-photocycloaddition of 4-arylidene-5(4*H*)-oxazolones **1** (Figure 2, past work, path a).⁴¹ This reaction takes place for only a narrow range of substituents, and the corresponding cyclobutanes were obtained as mixtures of four different isomers with similar molar ratios. However, in the case of the thiazolones studied here, the scope is much wider, and the stereoselectivity is markedly higher.

The NMR data for all cyclobutanes **3** studied showed the presence of species with high symmetry but were not conclusive because several isomers could fit with the experimental NMR data. As such, full characterization of the main isomer for cyclobutanes **3** was achieved by determining the X-ray crystal structures of derivatives **3g**, **3h**, and **3m**, which are shown in Figures 6, 7, and 8, respectively.




Figure 6. X-ray crystal structure of cyclobutane **3g**. Thermal ellipsoids are drawn at 50% probability.

All structures clearly show the formation of the cyclobutane core by [2 + 2]-cycloaddition of the respective thiazolones. The isomer characterized in all three cases is the ϵ -isomer (ϵ), according to the isomer assignment of Stoermer and Bachér,^{67,68} which is formed by the 1,3-head-to-tail coupling of two *Z*-thiazolones in a *syn* orientation. This ϵ -isomer is the same as that characterized as the major isomer in the [2 + 2]-photocycloaddition of oxazolones, thus suggesting that the dimerization of oxazolones and thiazolones follows the same orientation. The three structures are very similar, with the




Figure 7. X-ray crystal structure of cyclobutane **3h**. Thermal ellipsoids are drawn at 50% probability.




Figure 8. X-ray crystal structure of cyclobutane **3m**. Thermal ellipsoids are drawn at 50% probability.

cyclobutane core showing the 1,2-*cis*-2,3-*cis*-3,4-*cis* configuration. The cyclobutane rings are not planar and exhibit dihedral angles of C1-C2-C101-C2 (**3g**) = 18.1(3)°, C1-C9-C18-C26 (**3h**) = 19.7(3)°, and C2-C10-C2-C10 (**3m**) = 22.4(3)°, which are similar to those found in related cyclobutanes.⁴¹ In addition, the values for the remaining bond distances (Å) and angles (°) are in the usual range of values found in the literature for related structural arrangements.^{38,41,43,69–74}




Figure 9. Photocycloaddition of thiazolones **2** in methanol in the presence of the Lewis acid $\text{BF}_3\cdot\text{OEt}_2$

The characterization of the main isomer in compounds **3g**, **3h**, and **3m** as the ϵ -isomer allows us to extrapolate this assignment to the remaining cyclobutanes **3** prepared here even though we were unable to characterize them all by X-ray diffraction. An additional argument in this direction is the comparison of the NMR chemical shifts for the ^1H and ^{13}C nuclei of the cyclobutane ring in **3**, which exhibit values that appear in very narrow ranges, thereby suggesting quite similar environments.

Effect of Lewis Acids (BF_3) on the [2 + 2]-Photocycloaddition of Thiazolones **2.** As mentioned in the Introduction, the presence of Lewis acids can change the rate, orientation, and/or selectivity of a given reaction.^{23,28,53–62} In order to determine the influence of Lewis acids in this particular photochemical reaction, we irradiated suspensions of selected examples of thiazolones **2** with blue light (Kessil lamp, 456 nm), in methanol, in the presence of $\text{BF}_3\cdot\text{OEt}_2$. The optimized amount of $\text{BF}_3\cdot\text{OEt}_2$ was four equivalents with respect to thiazolone **2**. After irradiation for 24 h, the conversion of **2** was complete, and cyclobutanes **4** (represented in Figure 9) were isolated by simple filtration of the resulting suspensions (see Experimental Section and Supporting Information). The full characterization of these cyclobutanes **4** showed that they were obtained as single isomers in all cases studied (see below). As such, the reaction in the presence of a Lewis acid (BF_3) gives a cyclobutane with the same orientation as in its absence but with full stereoselectivity, thereby improving our previous results. However, no acceleration was observed. As a result, a more restricted scope was examined.

The characterization of compounds **4** by HRMS and NMR spectroscopy clearly shows the formation of a cyclobutane core in which one of the thiazolones remains unchanged while the other has undergone a ring-opening reaction by methanolysis, thus giving the corresponding ester and thioamide fragments. The HRMS data for cyclobutanes **4a**, **4b**, **4d**, and **4e** reflect the dimerization of the corresponding thiazolones **2** and the incorporation of a molecule of methanol for each dimer of cyclobutane. The ^1H NMR spectra of **4a–4e** show signals corresponding to the presence of a single isomer in each case; in other words, the reaction is totally stereoselective for the cases studied. The ring-opening reaction is evidenced by the observation of peaks due to the ester fragment (at around 3.8 ppm) and the NH proton (a broad signal at around 8.5–8.7

ppm) with a relative intensity of 3:1. The presence of a single peak for the two chemically equivalent cyclobutane CH protons (4.8–4.9 ppm, relative intensity 2) shows that, despite the loss of symmetry produced by the ring-opening reaction, the two ArC(H) groups of the cyclobutane are still equivalent. The ^{13}C NMR spectra of **4a–4e** also show signals in agreement with the ring-opening reaction of the only heterocycle. In this respect, peaks at around 205–206 (SC=O) and 166–167 ppm (SC=N) suggest the presence of a thiazolone ring, while peaks at around 198 (HNC=S) and 169 ppm (COO) confirm the presence of ester and thioamide groups. Moreover, three different signals are observed for the cyclobutane ring, one for the two chemically equivalent CH carbons (in the 55 ppm region) and two for the quaternary carbons (at about 90 and 67 ppm).

As discussed for cyclobutanes **3**, there is more than one isomer whose structure fits with the HRMS and NMR data for cyclobutanes **4**. In this case, there are four possible structures (*syn-ε*, *syn-εpi*, *anti-εpi*, and *syn-peri*);⁴¹ therefore, the X-ray crystal structure of **4b** was determined to complete the structural characterization. Crystals were obtained by slow diffusion of *n*-pentane into a solution of crude **4b** in CH_2Cl_2 at -18°C , and the structure obtained is shown in Figure 10.

The structure of cyclobutane **4b** shows that the isomer obtained is the ϵ -isomer, which is formed by the 1,3-head-to-tail coupling of two thiazolones in a *syn* orientation. The cyclobutane core of **4b** is not planar, showing a value for the C4–C1–C2–C3 dihedral angle of $19.1(1)^\circ$, which is identical to those found in the structures of **3g**, **3h**, and **3m**. Other internal parameters of the cyclobutane ring are also identical (within experimental error) to those found in **3g**, **3h**, and **3m**. The structure also confirms the ring-opening reaction by methanolysis at one of the thiazolones and the corresponding presence of ester and thioamide fragments, both of which show bond distance and angle values in agreement with those found in the literature for similar types of bonds.⁷⁴

In light of the crystal structure of **4b**, it can be concluded that photocycloaddition in methanol in the presence of BF_3 gives cyclobutanes **4**, and that cyclobutanes **3** are formed in the absence of BF_3 . This reaction takes place with exactly the same orientation because the same isomer out of the 11 possible cyclobutane isomers is obtained in both cases (ϵ -isomer). However, the reaction affords slightly different compounds as **3** contains two unaltered thiazolone rings, whereas **4** contains




Figure 10. X-ray crystal structure of cyclobutane **4b**. Thermal ellipsoids are drawn at 50% probability.

only one. This suggests that the Lewis acid BF_3 has a small but important influence as, although neither the rate nor the orientation of the reaction are affected, the ring-opening reaction is favored in the presence of the Lewis acid.

We have studied the interaction between thiazolones **2** and BF_3 in MeOH both in the ground state and in the excited state. Thiazolone **2b** was selected as a representative example. To analyze the interaction in the ground state, a solution of **2b** in CD_3OD was treated with increasing amounts of $\text{BF}_3 \cdot \text{OEt}_2$ until the molar ratio 1:4 was reached, and the result of each addition was monitored by ^1H NMR spectroscopy (see [Supporting Information](#)). A comparison of the NMR spectra showed that there is no detectable interaction on the NMR time scale as all spectra were identical, and no signal underwent a change in its chemical shift. This suggests that either the interaction is very weak or it occurs to such a small extent that it cannot be detected by NMR spectroscopy. As for the excited state, the fluorescence of thiazolone **2b** was examined in the absence and presence of $\text{BF}_3 \cdot \text{OEt}_2$ ([Supporting Information](#)) in methanol.

Thiazolone **2b** is fluorescent and shows an emission maximum at 459 nm when excited at 390 nm. After the addition of $\text{BF}_3 \cdot \text{OEt}_2$ (1–4 equiv), no changes were detected in either the maximum of the emission or its intensity. These results suggest that the Lewis acid does not have a marked influence on either the excited state or the ground state. However, the different structure of cyclobutanes **3** and **4** shows that an interaction with the Lewis acid must occur at some point in the reaction, and given the lack of reaction observed between **2b** and BF_3 , this probably occurs after the formation of cyclobutane **3**. To check this, we treated cyclobutane **3a** with $\text{BF}_3 \cdot \text{OEt}_2$ in methanol for 24 h at room temperature and in the dark. The formation of **4a** was evident after this time, thus suggesting that the role of BF_3 is related to the promotion of the ring-opening reaction, as shown in [Figure 11](#), rather than to the [2 + 2]-photocycloaddition.

Ring-Opening Reaction of Thiazolones 2: Synthesis of 4,5-Dihydrothiazoles (5, 6) and Thiazoles (7). The easy ring-opening reaction undergone by **3** to give **4** prompted us to study the opening of the remaining thiazolone ring in **4**. The opening of both heterocycles should produce cyclobutanes structurally analogous to diaminotruaxilic bis-amino acids but containing sulfur in their structure. In a first attempt, we tested the classical process, namely, heating cyclobutanes **3c** and **3d** with a catalytic amount of a base (NaOMe) in alcohol (MeOH).⁷⁵ Surprisingly, this reaction afforded the 4,5-dihydrothiazoles **5c** and **5d** as a mixture of *cis*- and *trans*-diastereoisomers, as shown in [Figure 12](#) (upper reaction).

The transformation shown in the upper reaction of [Figure 12](#) suggests that the reaction is most likely related to the intrinsic reactivity of the exocyclic $\text{C}(\text{H})=\text{C}$ bond in thiazolone **2** rather than to that of the cyclobutane skeleton in **3**. For that reason, we studied the reactivity of thiazolones **2c** and **2d** with NaOMe in MeOH as a solvent, and the results are also shown in [Figure 12](#) (lower reaction). As expected, the treatment of **2c** and **2d** with base in alcohol gave the dihydrothiazoles **5c** and **5d** in virtually the same yields and diastereomeric excess as obtained when **3c** and **3d** were used as precursors instead. This suggests that, when heating under basic conditions, cyclobutanes **3** are not stable and a retro-[2 +




Figure 11. Proposal of the mechanism for the BF_3 -promoted ring-opening reaction.




Figure 12. Synthesis of 4,5-dihydrothiazoles **5** by treatment of cyclobutanes **3** with NaOMe in MeOH.




Figure 13. Reactivity of thiazolones **2** with base in alcohol to give dihydrothiazoles (**5** and **6**) and thiazoles (**7**). Yields (%) correspond to the pure isolated *trans*-isomer.

2] reaction can take place to regenerate thiazolones **2**, which subsequently react with a base to give **5**.

Compounds **5c** and **5d** were characterized by HRMS and NMR spectroscopy. The ^1H NMR spectra show two characteristic AB spin systems centered around 5.4 ppm, assigned to the two aliphatic protons of the (N)CH—CH (S) moiety. The value of the $^3J_{\text{HH}}$ coupling constant between these two protons is diagnostic for the determination of the configuration of each diastereoisomer. Thus, the major species shows a value for the $^3J_{\text{HH}}$ coupling constant of 6.5 Hz, which is typical for *trans* geometries, whereas the value found for the minor isomer is around 10 Hz, thus suggesting a *cis* arrangement.⁷⁶ The higher abundance of the *trans*-isomer is in good agreement with the lower intramolecular repulsions in

this isomer. These two protons correlate (^1H – ^{13}C HSQC spectra) with two C atoms at around 87 (CHN) and 55 ppm (CHS), thus showing their aliphatic character. In addition, the peak at around 194–196 ppm for thiazolones **2** (around 205–208 ppm in cyclobutanes **3**), assigned to the thiocarbonyl group (S—C=O), has disappeared, and a new peak is now observed in the 170–172 ppm region. This suggests the formation of a new heterocycle, namely the 4,5-dihydrothiazole shown in Figure 12.

This synthetic method for the preparation of dihydrothiazoles from 4-arylidene-5(4H)thiazolones **2** is novel as, to the best of our knowledge, only one previous example has been reported in the literature.⁷⁷ In that case, the reaction was performed using NaOH in water to afford the corresponding




Figure 14. Mechanistic proposal for the synthesis of dihydrothiazoles 5 (or 6) from thiazolones 2.




Figure 15. Reactivity of thiazolones 2 with MeOH in the presence of BF₃; synthesis of dihydrothiazoles 5.

carboxylic acid.⁷⁷ Dihydrothiazoles are interesting materials due to their properties, and different synthetic methods have been reported for their preparation, most of them starting from aminothiols.^{78–89} Dihydrothiazoles are versatile intermediates for the synthesis of high-value-added compounds, for instance β -cysteine and derivatives,^{90–94} are present in flavours⁹⁵ and in natural products,^{96–99} and show a remarkable pharmacological activity.^{100–102} For all of these reasons, we decided to explore this almost unprecedented synthesis of dihydrothiazoles from thiazolones 2 in more detail. The results are presented in Figure 13.

The treatment of thiazolones 2 with NaEtO in ethanol at reflux temperature gave the corresponding dihydrothiazoles 6, as shown in Figure 13. After the reaction, the ethanol was evaporated to dryness, the residue was extracted with CH₂Cl₂, and all insoluble materials were removed by filtration.

Evaporation of the solvent gave an oily residue, which was shown by ¹H NMR spectroscopy to be a mixture of the two diastereoisomers of dihydrothiazoles 6 in a *trans/cis* molar ratio in the range 86:14 to 90:10. As such, the reaction takes place with a remarkable diastereomeric excess, which is even higher than when methanol was used as a solvent. The major *trans*-isomer could be isolated in pure form from that mixture by column chromatography (see Experimental Section), while the minor *cis*-isomer could not be isolated in sufficient quantity to be characterized in most cases. The reaction shows an adequate scope, as it works in moderate to good yields for both electron-donating (**6c**, **6i**, **6m**) and electron-withdrawing (**6h**, **6n**) substituents in the 5-aryl ring. In addition, the reaction tolerates substituents at the *ortho*-, *meta*-, and *para*-positions of the aryl ring. In the case of thiazolone **2n**, the formation of the thiazole **7n** as the major reaction product was observed. This




Figure 16. Mechanistic proposal for the formation of dihydrothiazoles in the presence of BF_3 .

compound was also purified and separated from **6n** by column chromatography. The absence of the diagnostic AB spin system at around 5.3–5.4 ppm in the ^1H NMR spectrum of **7n**, and the corresponding carbons at 86 ppm and 55 ppm in the ^{13}C NMR spectrum, as well as the presence of two new quaternary C atoms at 142 ppm, confirms the formation of thiazole **7n**, the molecular structure of which determined by X-ray diffraction methods (Figure 13). The formation of thiazole **7n** in the reaction medium is likely due to aerobic oxidation of the precursor dihydrothiazole, which is a well-known reaction.¹⁰³ When microwaves were used instead of a conventional heating source, as in the case of the 4- NO_2 -substituted thiazolone **2g**, complete transformation into thiazole **7g** was observed in just one minute, thus meaning that formation of the dihydrothiazole is accelerated, as is its oxidation. For that reason, only conventional heating was used.

The mechanism proposed for the synthesis of dihydrothiazoles **5** or **6** from thiazolones **2** is shown in Figure 14. The reaction seems to start with a nucleophilic attack of the alkoxide at the carbonyl carbon to form the corresponding ester group and the thioamidate fragment. Subsequent intramolecular S-attack of the sulfide at the C(H) carbon of the exocyclic C(H)=C double bond, followed by protonation of the stabilized enolate generated, results in the formation of the final dihydrothiazoles.

The easy ring-opening reactions undergone by cyclobutanes **3** to give cyclobutanes **4** shown in Figures 9 and 11 suggest that the Lewis acid BF_3 fosters the attack of nucleophiles at the carbonyl carbon, which should, in principle, favor the formation of dihydrothiazoles from thiazolones. With this in mind, we attempted the reaction of thiazolones **2** with methanol, in the presence of the Lewis acid $\text{BF}_3 \cdot \text{OEt}_2$ and in the absence of a base. The results of these reactions are shown in Figure 15.

The treatment of thiazolones **2** with $\text{BF}_3 \cdot \text{OEt}_2$ (4 equiv) in methanol at reflux temperature for 18 h resulted in the formation of the corresponding dihydrothiazoles **5** in good to moderate yields. The reaction does not take place at room temperature, with thiazolone **2** being recovered unchanged. At shorter reaction times (2 h) in refluxing methanol, we observed low conversions (less than 10%), along with the formation of **5** in a more or less equimolar mixture of the two

diastereoisomers (range between 1.2:1 to 1.5:1). No reaction was observed in refluxing methanol in the absence of BF_3 . As such, in the presence of BF_3 , both high temperatures and long reaction times are needed to achieve full conversion of thiazolones **2** into dihydrothiazoles **5**, although a base is no longer required. The reaction is tolerant to the presence of electron-donating (Me, OMe) and electron-withdrawing (F, Cl, Br, CF_3) substituents at different positions of the aryl ring, thus meaning that the reaction shows an adequate scope. The main difference between this process and the reaction performed in the presence of a base (Figures 12 and 13) is the diastereoselectivity, which is moderate to high in the presence of a base but very low or even nonexistent in the presence of BF_3 . Unfortunately, we have no reasonable explanation for this finding. Our mechanistic proposal to explain the role of the Lewis acid in this reaction is presented in Figure 16. Coordination of the carbonyl oxygen to BF_3 increases the electrophilic character of the carbonyl carbon (as in Figure 11), which is, therefore, more susceptible to attack by methanol. The decoordination of BF_3 is followed by the formation of the sulfide, which can attack the exocyclic C(H)=C bond (see Figure 14).

CONCLUSION

In summary, new (*Z*)-4-arylidene-5(4*H*)-thiazolones **2** have been prepared by treatment of oxazolones with thioacetic acid. These thiazolones have been shown to be convenient and versatile precursors for the synthesis of a wide variety of carbonyl and heterocycles with high selectivity. The irradiation of thiazolones **2** with blue light (465 nm) results in the formation of diamino-truxillic-type cyclobutanes **3** by head-to-tail 1,3-*syn* coupling [2 + 2]-photocycloaddition of thiazolones **2**. The reaction shows a high stereoselectivity as cyclobutanes **3** are obtained mostly as the ϵ isomer. When the photochemical reaction is performed in the presence of a Lewis acid ($\text{BF}_3 \cdot \text{OEt}_2$), the reaction follows the same orientation (head-to-tail 1,3-coupling), but an additional ring-opening reaction is observed, due to bonding of the BF_3 , thus giving a different family of truxillic cyclobutanes **4**. The role of the Lewis acid is to foster the electrophilic character of the carbonyl carbon, thereby favoring the ring-opening reaction. In addition, treatment of **2** with base NaOR in alcohol ROH affords

dihydrothiazoles **5**, **6** via a ring-opening reaction followed by S-intramolecular attack at the exocyclic C(H)=C bond. The reaction is highly stereoselective, with the *trans*-isomer being obtained as a major isomer in all cases studied. Dihydrothiazoles **5** can also be obtained by treatment of the thiazolone **2** with alcohol in the presence of BF₃ but in the absence of a base. In this case, the reaction shows a broader scope, and it seems that the role of BF₃ is to increase the electrophilic character of both the carbonyl carbon and the vinyl carbon.

EXPERIMENTAL SECTION

General Methods. All solvents used are commercial-grade and were used as received. All reactions were performed at open-air without special caution against the moisture and oxygen, except the syntheses of compounds **4**, which were carried out under Ar atmosphere using dry and deoxygenated methanol. Flash column liquid chromatographies were performed on silica gel (70–230 μm) or aluminum oxide 90 neutral (50–200 μm), eluting with the solvents specified on each case. Elemental analyses (CHNS) were carried out on a Perkin-Elmer 2400 Series II microanalyzer. Infrared spectra (4000–380 cm⁻¹) were recorded on a Perkin-Elmer Spectrum-100 IR spectrophotometer. ¹H, ¹³C, and ¹⁹F NMR spectra were recorded in CDCl₃ or CD₂Cl₂ solutions at 25 °C on Bruker AV300 or AV500 spectrometers (δ in ppm, J in Hz) at ¹H operating frequency of 300.13 or 500.13 MHz, respectively. ¹H and ¹³C spectra were referenced using the solvent signal as internal standard, while ¹⁹F spectra were referenced to CFCl₃. The assignment of ¹H NMR peaks has been performed through standard 2D ¹H–COSY (2K points in t₂ using a spectral width of 12 ppm; 128 t₁ experiments were recorded and zero-filled to 1K; for each t₁ value, two scans were signal-averaged using a recycle delay of 1 s) and selective 1D ¹H–NOESY experiments. Typical mixing times in the case of selective 1D–NOESY experiments were in the range 1.0–2.0 s, as a function of the irradiated signal. These values of optimized mixing times were set equal to the longitudinal relaxation time T₁, determined using the inversion–recovery sequence. The ¹³C NMR peaks were identified using standard ¹H–¹³C edited-HSQC and ¹H–¹³C HMBC 2D experiments. In both cases, 4K points in t₂ using spectral widths of 10 ppm (¹H) and 200 ppm (¹³C) were used, with averaged values of the coupling constants ¹J_{CH} = 145 Hz and long-range ⁿJ_{CH} = 10 Hz. Typically, 128 t₁ experiments were recorded and zero-filled to 1 K. For each t₁ value, 8 (HSQC) or 32 (HMBC) scans were signal-averaged using a recycle delay of 1 s. ESI (ESI⁺) mass spectra were recorded using an Esquire 3000 ion-trap mass spectrometer (Bruker Daltonics GmbH) equipped with a standard ESI/APCI source. Samples were introduced by direct infusion with a syringe pump. Nitrogen served both as the nebulizer gas and the dry gas. MALDI mass spectra were recorded using a Bruker MicroFlexTM or a Bruker AutoFlexTMIII spectrometer, equipped with a time-of-flight mass analyzer, and using DIT (dithranol) as a matrix. The sample was dissolved in CH₂Cl₂. The HRMS mass spectra were recorded using a MicroToF Q, API-Q-ToF ESI with a mass range from 20 to 3000 m/z and mass resolution of 15000 (fwhm). The absorption spectra in the UV–visible region were measured on a Thermo Scientific Evolution 600 UV–vis spectrophotometer using quartz SUPRAXIL cuvettes, light path 10 mm. The oxazolones **1a–1o** used as starting materials were synthesized according to published methods.^{104–113}

Irradiation Setup. The irradiation setup consists of a round-bottom flask irradiated by either a printed circuit board (PCB) formed by 24 LEDs bulbs (Topbright) of a 10 mm diameter, each irradiating at 465 nm, or a commercial Kessil lamp irradiating at 456 nm. The LEDs are serially connected in blocks of 6. The output power per LED unit (blue, 465 nm) is 250 mW. The optical output power of the PCB of LEDs measured with a photometer (PM100D, Thorlabs) was 1 W, so the maximal power provided by the PCB is 24 W. The PCB (dimensions: 7 cm × 6 cm) and the flask are placed inside a custom-built setup for fixing the light source and the sample container and dissipate the excess heating. A concave mirror is placed

in front of the PCB to maximize the light that irradiates the LEDs. The Kessil lamp is the PR160L-456 nm model, with a maximal power of 40 W. The intensity of the lamp can be tuned, and different powers were tested. Those specified in each case gave the maximum yield.

X-ray Crystallography. Single crystals of **3g**, **3h**, **4b**, and **7n** of suitable quality for X-ray diffraction measurements were grown by slow diffusion of *n*-pentane into CH₂Cl₂ solutions of the crude product at –18 °C for several weeks, while those of **3m** were obtained by slow evaporation of a solution of the product in CH₂Cl₂. A single crystal was mounted in each case at the end of a quartz fiber in a random orientation. The crystal was fixed to the fiber with epoxy resin (**3g**) or covered with perfluorinated oil and placed under a cold stream of N₂ gas (**3h**, **3m**, **4b**, **7n**). The data collections were performed at 293(2) K on an Oxford Diffraction Xcalibur Sapphire3 diffractometer (**3g**) or at 100(2) K on Bruker D8 Venture (**3h**, **3m**) or Bruker APEX CCD (**4b**, **7n**) diffractometers using graphite-monochromated Mo Kα radiation (λ = 0.71073 Å). A hemisphere of data was collected based on ω-scan and φ-scan runs. The diffraction frames were integrated using the programs CrysAlis RED¹¹⁴ and SAINT,¹¹⁵ and the integrated intensities were corrected for absorption with SADABS.¹¹⁶ The structures were solved and developed by Fourier methods.¹¹⁷ All non-hydrogen atoms were refined with anisotropic displacement parameters. The H atoms were placed at idealized positions and treated as riding atoms. Each H atom was assigned an isotropic displacement parameter equal to 1.2 times the equivalent isotropic displacement parameter of its parent atom. The structures were refined to F_o², and all reflections were used in the least-squares calculations.¹¹⁸ CCDC 1912941 (**3g**), 1912942 (**7n**), 1958992 (**3h**), 1958993 (**3m**), and 1999650 (**4b**) contains the supplementary crystallographic data for this paper and can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.

General Procedure for the Synthesis of (Z)-2-Phenyl-4-arylidene-5(4H)-thiazolones **2a–2o.** The synthesis of the thiazolones **2a–2o** has been carried out following the same experimental procedure as that reported by Rao and Filler,⁴⁶ which in turn is based in the original work of Behringer et al.^{63,64} Thiazolones **2a–2c** have been previously described, although **2b** was prepared using a different method.^{65,66} Thiazolones **2e**, **2f**, **2g**, **2h**, and **2j** appear on Scifinder, but either no references are associated with their synthesis, or no details of their preparation and characterization can be found in the literature associated. Therefore, we present here the full synthesis and characterization of thiazolones **2d–2o**.

(Z)-4-(4-Fluorobenzylidene)-2-phenyl-5(4H)-thiazolone **2d.** The oxazolone **1d** (2.5 g, 9.3 mmol), thioacetic acid (2.0 mL, 28.4 mmol) and NEt₃ (0.1 mL) were heated in an oil bath at 70 °C while stirred for 18 h. During this time the oxazolone dissolved, giving a dark solution, and after some minutes a deep-colored solid precipitated. After the reaction time the mixture was left to reach room temperature and ethanol (30 mL) was added to complete the precipitation. The yellow solid thus formed was filtered, washed thoroughly with ethanol (120–150 mL) until the characteristic smell of thioacetic acid disappeared, dried by suction, and characterized as **2d**. Obtained: 1.64 g (62% yield). ¹H NMR (CD₂Cl₂, 300.13 MHz): δ = 8.30 (dd, 2H, H₂/H₆, C₆H₄F, ³J_{HH} = 8.7 Hz, ⁴J_{HF} = 5.7 Hz), 8.00 (d, 2H, H₉, Ph, ³J_{HH} = 6.5 Hz), 7.61–7.50 (m, 3H, H_p+2H_m, Ph), 7.18 (t, 2H, H₃/H₅, ³J_{HH} ≈ ³J_{HF} = 8.7 Hz), 7.17 (s, 1H, H_{vinyl}). ¹⁹F NMR (CD₂Cl₂, 282.4 MHz): δ = –107.41 (tt, ³J_{FF} = 8.7 Hz, ⁴J_{FF} = 3.1 Hz). ¹³C{¹H} NMR (CD₂Cl₂, 75.5 MHz): δ = 194.7 (CO), 167.6 (NCS), 165.0 (d, C₄F, ¹J_{CF} = 254 Hz), 146.4 (=C), 136.0 (d, 2CH, C₂/C₆, ³J_{FC} = 8.7 Hz), 133.9 (C, C_v, Ph), 133.3 (CH, C_p, Ph), 130.8 (d, C, C₁, C₆H₄F, ⁴J_{FC} = 3.3 Hz), 130.0 (d, CH, C_{vinyl}, ⁵J_{FC} = 1.7 Hz), 129.6 (2CH, C_m, Ph), 128.8 (2CH, C_o, Ph), 116.7 (d, 2CH, C₃/C₅, C₆H₄F, ²J_{FC} = 22.0 Hz). HRMS (ESI⁺) [m/z]: calcd for [C₁₆H₁₀FNNaOS]⁺ = [M + Na]⁺, 306.0359; found, 306.0349. IR (ν, cm⁻¹): 1682 (CO, vs).

(Z)-4-(4-Chlorobenzylidene)-2-phenyl-5(4H)-thiazolone **2e.** Thiazolone **2e** was obtained following the same experimental procedure than the described for **2d**. Therefore, oxazolone **1e** (2.5 g, 8.8 mmol) was reacted with thioacetic acid (2 mL) and NEt₃ (0.1 mL) for 18 h at 70 °C to give **2e** as a deep yellow solid. Obtained: 1.55 g (59%

yield). ^1H NMR (CD_2Cl_2 , 300.13 MHz): δ = 8.25 (AA'BB' spin system, 2H, H_3/H_5 , $\text{C}_6\text{H}_4\text{Cl}$), 8.04 (dd, 2H, H_6 , Ph, $^3J_{\text{HH}} = 8.2$ Hz, $^4J_{\text{HH}} = 1.5$ Hz), 7.64–7.55 (m, 3H, $\text{H}_p + 2\text{H}_m$, Ph), 7.48 (AA'BB' spin system, 2H, H_2/H_6 , $\text{C}_6\text{H}_4\text{Cl}$), 7.18 (s, 1H, H_{vinyl}). $^{13}\text{C}\{^1\text{H}\}$ NMR (CD_2Cl_2 , 75.5 MHz): δ = 194.1 (CO), 167.5 (NCS), 146.4 (=C), 137.3 (C, C_4 , $\text{C}_6\text{H}_4\text{Cl}$), 134.2 (2CH, C_3/C_5 , $\text{C}_6\text{H}_4\text{Cl}$), 133.3 (C_1 , $\text{C}_6\text{H}_4\text{Cl}$), 132.9 (CH, C_p , Ph), 132.4 (C_i , Ph), 129.2 (CH, C_{vinyl}), 129.2 (2CH, C_2/C_6 , $\text{C}_6\text{H}_4\text{Cl}$), 129.0 (2CH, C_m , Ph), 128.3 (2CH, C_o , Ph). HRMS (ESI $^+$) [m/z]: calcd for [$\text{C}_{16}\text{H}_{10}\text{ClNNaOS}$] $^+$ = [$\text{M} + \text{Na}$] $^+$, 322.0064; found, 322.0053.

(Z)-4-(4-Bromobenzylidene)-2-phenyl-5(4H)-thiazolone 2f. Thiazolone **2f** was obtained following the same experimental procedure than the described for **2d**. Therefore, oxazolone **1f** (2.5 g, 7.6 mmol) was reacted with thioacetic acid (2 mL) and NEt_3 (0.1 mL) for 18 h at 70 °C to give **2f** as a deep yellow solid. Obtained: 1.19 g (45% yield). ^1H NMR (CDCl_3 , 300.13 MHz): δ = 8.13 (d, 2H, $\text{H}_3 + \text{H}_5$, $\text{C}_6\text{H}_4\text{Br}$, $^3J_{\text{HH}} = 8.5$ Hz), 8.01 (d, 2H, H_6 , Ph, $^3J_{\text{HH}} = 6.7$ Hz), 7.61 (d, 2H, $\text{H}_2 + \text{H}_6$, $\text{C}_6\text{H}_4\text{Br}$, $^3J_{\text{HH}} = 8.5$ Hz), 7.57–7.51 (m, 3H, $\text{H}_p + 2\text{H}_m$, Ph), 7.16 (s, 1H, H_{vinyl}). $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 75.5 MHz): δ = 194.5 (CO), 167.7 (NCS), 146.7 (=C), 134.5 (2CH, $\text{C}_3 + \text{C}_5$, $\text{C}_6\text{H}_4\text{Br}$), 133.5 (C_1 , $\text{C}_6\text{H}_4\text{Br}$), 133.0 (CH, C_p , Ph), 132.8 (C_i , Ph), 132.4 (2CH, $\text{C}_2 + \text{C}_6$, $\text{C}_6\text{H}_4\text{Br}$), 129.8 (CH, C_{vinyl}), 129.2 (2CH, C_m , Ph), 128.5 (2CH, C_o , Ph), 126.3 (C_4 , C-Br, $\text{C}_6\text{H}_4\text{Br}$). HRMS (ESI $^+$) [m/z]: calcd for [$\text{C}_{16}\text{H}_{10}\text{BrNNaOS}$] $^+$ = [$\text{M} + \text{Na}$] $^+$, 365.9559; found, 365.9551.

(Z)-4-(4-Nitrobenzylidene)-2-phenyl-5(4H)-thiazolone 2g. Thiazolone **2g** was obtained following the same experimental procedure than the described for **2d**. Therefore, oxazolone **1g** (2.5 g, 8.5 mmol) was reacted with thioacetic acid (2 mL) and NEt_3 (0.1 mL) for 18 h at 70 °C to give **2g** as a deep yellow solid. Obtained: 1.02 g (38% yield). ^1H NMR (CDCl_3 , 300.13 MHz): δ = 8.45 (AA'BB' spin system, 2H, H_3/H_5 , $\text{C}_6\text{H}_4\text{NO}_2$), 8.35 (AA'BB' spin system, 2H, H_2/H_6 , $\text{C}_6\text{H}_4\text{NO}_2$), 8.07 (d, 2H, H_6 , Ph, $^3J_{\text{HH}} = 7.2$ Hz), 7.66–7.57 (m, 3H, $\text{H}_p + 2\text{H}_m$, Ph), 7.24 (s, 1H, H_{vinyl}). $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 75.5 MHz): δ = 195.3 (CO), 169.1 (NCS), 148.4 (C_4 , $\text{C}_6\text{H}_4\text{NO}_2$), 139.7 (C_1 , $\text{C}_6\text{H}_4\text{NO}_2$), 133.5 (CH, C_p , Ph), 133.3 (2CH, C_3/C_5 , $\text{C}_6\text{H}_4\text{NO}_2$), 129.2 (2CH, C_m , Ph), 128.6 (2CH, C_o , Ph), 127.0 (CH, C_{vinyl}), 123.9 (2CH, C_2/C_6 , $\text{C}_6\text{H}_4\text{NO}_2$). Due to low solubility some quaternary ^{13}C signals (Ci of Ph and = C of the arylidene fragment) were missing. HRMS (ESI $^+$) [m/z]: calcd for [$\text{C}_{16}\text{H}_{10}\text{N}_2\text{NaO}_3\text{S}$] $^+$ = [$\text{M} + \text{Na}$] $^+$, 333.0310; found, 333.0317. IR (ν , cm^{-1}): 1696 (vs).

(Z)-4-(4-Trifluoromethylbenzylidene)-2-phenyl-5(4H)-thiazolone 2h. Thiazolone **2h** was obtained following the same experimental procedure than the described for **2d**. Therefore, oxazolone **1h** (2.5 g, 7.9 mmol) was reacted with thioacetic acid (2 mL) and NEt_3 (0.1 mL) for 18 h at 70 °C to give **2h** as a pale-yellow solid. Obtained: 1.84 g (70% yield). ^1H NMR (CDCl_3 , 300.13 MHz): δ = 8.34 (AA'BB' spin system, 2H, H_2/H_6 , $\text{C}_6\text{H}_4\text{CF}_3$), 8.01 (dd, 2H, H_6 , Ph, $^3J_{\text{HH}} = 8.2$ Hz, $^4J_{\text{HH}} = 1.5$ Hz), 7.72 (AA'BB' spin system, 2H, H_3/H_5 , $\text{C}_6\text{H}_4\text{CF}_3$), 7.60–7.50 (m, 3H, $\text{H}_p + 2\text{H}_m$, Ph), 7.19 (s, 1H, H_{vinyl}). ^{19}F NMR (CDCl_3 , 282.4 MHz): δ = -62.97 (s). $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 75.5 MHz): δ = 194.4 (CO), 168.9 (NCS), 147.7 (=C), 137.1 (q, C_1 , $\text{C}_6\text{H}_4\text{CF}_3$, $^5J_{\text{CF}} = 1.4$ Hz), 133.3 (CH, C_p , Ph), 133.2 (C_i , Ph), 133.1 (2CH, C_2/C_6 , $\text{C}_6\text{H}_4\text{CF}_3$), 132.2 (q, C_4 , $\text{C}_6\text{H}_4\text{CF}_3$, $^2J_{\text{CF}} = 43$ Hz), 129.2 (2CH, C_m , Ph), 128.7 (CH, C_{vinyl}), 128.6 (2CH, C_o , Ph), 125.8 (2CH, C_3/C_5 , $\text{C}_6\text{H}_4\text{CF}_3$, $^3J_{\text{CF}} = 3.8$ Hz), 120.4 (q, CF_3 , $^1J_{\text{CF}} = 272$ Hz). Anal. Calcd for $\text{C}_{17}\text{H}_{10}\text{F}_3\text{NOS}$: C, 61.26; H, 3.02; N, 4.20; S, 9.62. Found: C, 60.94; H, 3.12; N, 3.91; S, 9.93.

(Z)-4-(2-Methoxybenzylidene)-2-phenyl-5(4H)-thiazolone 2i. Thiazolone **2i** was obtained following the same experimental procedure than the described for **2d**. Therefore, oxazolone **1i** (2.5 g, 8.9 mmol) was reacted with thioacetic acid (2 mL) and NEt_3 (0.1 mL) for 18 h at 70 °C to give **2i** as a pale-yellow solid. Obtained: 0.80 g (30% yield). ^1H NMR (CDCl_3 , 300.13 MHz): δ = 8.95 (d, 1H, H_6 , $\text{C}_6\text{H}_4\text{OMe}$, $^3J_{\text{HH}} = 7.8$ Hz), 8.02 (d, 2H, H_6 , Ph, $^3J_{\text{HH}} = 6.5$ Hz), 7.90 (s, 1H, H_{vinyl}), 7.57–7.42 (m, 4H, H_p (Ph) + 2H_m (Ph) + H_4/H_5 ($\text{C}_6\text{H}_4\text{OMe}$)), 7.12 (t, 1H, H_4/H_5 , $\text{C}_6\text{H}_4\text{OMe}$, $^3J_{\text{HH}} = 7.6$ Hz), 6.94 (d, 1H, H_3 , $\text{C}_6\text{H}_4\text{OMe}$, $^3J_{\text{HH}} = 8.3$ Hz), 3.92 (s, 3H, OMe). $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 75.5 MHz): δ = 194.6 (CO), 165.9 (NSC), 160.1 (C_2 ,

C-OMe, $\text{C}_6\text{H}_4\text{OMe}$), 145.7 (=C), 133.6 (C_i , Ph), 133.5 (CH, C_6 , $\text{C}_6\text{H}_4\text{OMe}$), 133.2 (CH, C_4/C_5 , $\text{C}_6\text{H}_4\text{OMe}$), 132.4 (CH, C_p , Ph), 128.9 (2CH, C_m , Ph), 128.2 (2CH, C_o , Ph), 125.4 (CH, C_{vinyl}), 122.9 (C_1 , $\text{C}_6\text{H}_4\text{OMe}$), 121.0 (CH, C_4/C_5 , $\text{C}_6\text{H}_4\text{OMe}$), 110.8 (CH, C_3 , $\text{C}_6\text{H}_4\text{OMe}$), 55.7 (OMe). HRMS (ESI $^+$) [m/z]: calcd for [$\text{C}_{17}\text{H}_{13}\text{NNaO}_2\text{S}$] $^+$ = [$\text{M} + \text{Na}$] $^+$, 318.0559; found, 318.0555.

(Z)-4-(2-Chlorobenzylidene)-2-phenyl-5(4H)-thiazolone 2j. Thiazolone **2j** was obtained following the same experimental procedure than the described for **2d**. Therefore, oxazolone **1j** (2.5 g, 8.8 mmol) was reacted with thioacetic acid (2 mL) and NEt_3 (0.1 mL) for 18 h at 70 °C to give **2j** as a yellow solid. Obtained: 0.98 g (36% yield). ^1H NMR (CDCl_3 , 300.13 MHz): δ = 8.95 (dd, 1H, H_6 , $\text{C}_6\text{H}_4\text{Cl}$, $^3J_{\text{HH}} = 7.8$ Hz, $^4J_{\text{HH}} = 2.0$ Hz), 8.01 (m, 2H, H_6 , Ph), 7.75 (s, 1H, H_{vinyl}), 7.62–7.34 (m, 6H, H_p (Ph) + 2H_m (Ph) + $\text{H}_3/\text{H}_4/\text{H}_5$ ($\text{C}_6\text{H}_4\text{Cl}$)). $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 75.5 MHz): δ = 194.2 (CO), 168.3 (NSC), 147.2 (=C), 137.5, 131.8 (C_i/C_2 , $\text{C}_6\text{H}_4\text{Cl}$), 133.9 (CH, C_6 , $\text{C}_6\text{H}_4\text{Cl}$), 133.3 (C_i , Ph), 133.0 (CH, C_p , Ph), 131.7, 130.0, 127.1 (CH, $\text{C}_3/\text{C}_4/\text{C}_5$, $\text{C}_6\text{H}_4\text{Cl}$), 129.0 (2CH, C_m , Ph), 128.4 (2CH, C_o , Ph), 126.0 (CH, C_{vinyl}). HRMS (ESI $^+$) [m/z]: calcd for [$\text{C}_{16}\text{H}_{10}\text{ClNNaOS}$] $^+$ = [$\text{M} + \text{Na}$] $^+$, 322.0064; found, 322.0072.

(Z)-4-(2-Bromobenzylidene)-2-phenyl-5(4H)-thiazolone 2k. Thiazolone **2k** was obtained following the same experimental procedure than the described for **2d**. Therefore, oxazolone **1k** (2.5 g, 7.6 mmol) was reacted with thioacetic acid (2 mL) and NEt_3 (0.1 mL) for 18 h at 70 °C to give **2k** as a deep yellow solid. Obtained: 1.02 g (39% yield). ^1H NMR (CDCl_3 , 300.13 MHz): δ = 8.92 (dd, 1H, H_3 , $\text{C}_6\text{H}_4\text{Br}$, $^3J_{\text{HH}} = 8.0$ Hz, $^4J_{\text{HH}} = 1.7$ Hz), 8.01 (dd, 2H, H_6 , Ph, $^3J_{\text{HH}} = 8.2$ Hz, $^4J_{\text{HH}} = 1.5$ Hz), 7.70 (s, 1H, H_{vinyl}), 7.68 (dd, 1H, H_6 , $\text{C}_6\text{H}_4\text{Br}$, $^3J_{\text{HH}} = 8.0$ Hz, $^4J_{\text{HH}} = 1.2$ Hz), 7.60–7.45 (m, 4H, $\text{H}_p + 2\text{H}_m$ (Ph) + H_4 ($\text{C}_6\text{H}_4\text{Br}$)), 7.30 (td, 1H, H_5 , $\text{C}_6\text{H}_4\text{Br}$, $^3J_{\text{HH}} = 8.0$ Hz, $^4J_{\text{HH}} = 1.7$ Hz). $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 75.5 MHz): δ = 194.1 (CO), 168.3 (NCS), 147.2 (=C), 134.0 (CH, C_3 , $\text{C}_6\text{H}_4\text{Br}$), 133.4 (CH, C_5/C_6 , $\text{C}_6\text{H}_4\text{Br}$), 133.3 (C_i , Ph), 133.0 (CH, C_p , Ph), 131.9 (CH, C_3/C_6 , $\text{C}_6\text{H}_4\text{Br}$), 129.0 (2CH, C_m , Ph), 128.8 (CH, C_{vinyl}), 128.4 (2CH, C_m , Ph), 128.3 (2 overlapped carbons, $\text{C}_1 + \text{C}_2$, $\text{C}_6\text{H}_4\text{Br}$), 127.7 (CH, C_4 , $\text{C}_6\text{H}_4\text{Br}$). HRMS (ESI $^+$) [m/z]: calcd for [$\text{C}_{16}\text{H}_{10}\text{BrNNaOS}$] $^+$ = [$\text{M} + \text{Na}$] $^+$, 365.9559; found, 365.9548.


(Z)-4-(3,4-Dimethoxybenzylidene)-2-phenyl-5(4H)-thiazolone 2l. Thiazolone **2l** was obtained following the same experimental procedure than the described for **2d**. Therefore, oxazolone **1l** (2.5 g, 8.1 mmol) was reacted with thioacetic acid (2 mL) and NEt_3 (0.1 mL) for 18 h at 70 °C to give **2l** as a deep orange solid. Obtained: 1.59 g (60% yield). ^1H NMR (CDCl_3 , 300.13 MHz): δ = 8.29 (s, 1H, H_2 , C_6H_3), 7.97 (d, 1H, H_6 , Ph, $^3J_{\text{HH}} = 7.2$ Hz), 7.60 (d, 1H, H_6 , C_6H_3 , $^3J_{\text{HH}} = 8.4$ Hz), 7.55–7.48 (m, 3H, $2\text{H}_m + \text{H}_p$ (Ph)), 7.20 (s, 1H, H_{vinyl}), 6.94 (d, 1H, H_5 , C_6H_3 , $^3J_{\text{HH}} = 8.4$ Hz), 4.02 (s, 3H, OMe), 3.97 (s, 3H, OMe). $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 75.5 MHz): δ = 194.4 (CO), 165.1 (NCS), 152.3, 149.1 (2C, $\text{C}_3 + \text{C}_4$, C_6H_3), 144.5 (=C), 133.6 (C_i , Ph), 132.3 (CH, C_6 , C_6H_3), 131.7 (CH, C_{vinyl}), 129.0 (2CH, C_m , Ph), 128.9 (CH, C_p , Ph), 127.8 (2CH, C_o , Ph), 127.0 (C, C_1 , C_6H_3), 114.5 (CH, C_2 , C_6H_3), 110.9 (CH, C_5 , C_6H_3), 56.0 (OCH $_3$), 55.8 (OCH $_3$). HRMS (ESI $^+$) [m/z]: calcd for [$\text{C}_{18}\text{H}_{15}\text{NNaO}_3\text{S}$] $^+$ = [$\text{M} + \text{Na}$] $^+$, 348.0665; found, 348.0659. IR (ν , cm^{-1}): 1704 (vs), 1677.

(Z)-4-(3,4-Dimethylbenzylidene)-2-phenyl-5(4H)-thiazolone 2m. Thiazolone **2m** was obtained following the same experimental procedure than the described for **2d**. Therefore, oxazolone **1m** (2.5 g, 9.0 mmol) was reacted with thioacetic acid (2 mL) and NEt_3 (0.1 mL) for 18 h at 70 °C to give **2m** as a yellow solid. Obtained: 1.18 g (44% yield). ^1H NMR (CDCl_3 , 300.13 MHz): δ = 8.09 (d, 1H, H_6 , C_6H_3 , $^3J_{\text{HH}} = 8.0$ Hz), 8.05–8.02 (m, 3H, H_5 (C_6H_3) + 2H_m (Ph)), 7.59–7.52 (m, 3H, $\text{H}_p + 2\text{H}_m$, Ph), 7.29 (s, 1H, H_2 , C_6H_3), 7.23 (s, 1H, H_{vinyl}), 2.37 (s, 3H, Me, $\text{C}_6\text{H}_3(\text{Me})_2$), 2.36 (s, 3H, Me, $\text{C}_6\text{H}_3(\text{Me})_2$). $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 75.5 MHz): δ = 194.7 (CO), 165.7 (NCS), 145.5 (=C), 141.2 (C, C_6H_3), 137.2 (C, C_6H_3), 134.6 (CH, C_5 , C_6H_3), 133.6 (C_i , Ph), 132.4 (CH, C_{vinyl}), 131.9 (CH, C_p , Ph), 131.5 (C, C_6H_3), 131.0 (CH, C_6 , C_6H_3), 130.4 (CH, C_2 , C_6H_3), 128.9 (2CH, C_m , Ph), 128.1 (2CH, C_o , Ph), 20.2 (CH $_3$), 19.9 (CH $_3$). HRMS (ESI $^+$) [m/z]: calcd for [$\text{C}_{18}\text{H}_{15}\text{NNaOS}$] $^+$ = [$\text{M} + \text{Na}$] $^+$, 316.0767; found, 316.0771. IR (ν , cm^{-1}): 1687 (vs), 1652.

(*Z*)-4-(3,4-Dichlorobenzylidene)-2-phenyl-5(4*H*)-thiazolone **2n**. Thiazolone **2n** was obtained following the same experimental procedure than the described for **2d**. Therefore, oxazolone **1n** (2.5 g, 7.9 mmol) was reacted with thioacetic acid (2 mL) and NEt₃ (0.1 mL) for 18 h at 70 °C to give **2n** as a yellow solid. Obtained: 1.74 g (66% yield). ¹H NMR (CDCl₃, 300.13 MHz): δ = 8.49 (d, 1H, H₂, C₆H₃Cl₂, ⁴J_{FH} = 1.9 Hz), 8.06–8.02 (m, 3H, H₅/H₆(C₆H₃Cl₂) + 2H_m(Ph)), 7.63–7.55 (m, 4H, H₅/H₆(C₆H₃Cl₂) + 2H_m + H_p(Ph)), 7.12 (s, 1H, H_{vinyl}). ¹³C{¹H} NMR (CDCl₃, 75.5 MHz): δ = 194.1 (CO), 168.5 (NCS), 147.1 (=C), 145.1 (C, C₆H₃Cl₂), 135.3 (C, C₆H₃Cl₂), 134.2 (CH, C₆, C₆H₃Cl₂), 133.7 (2C overlapped, C_i(Ph) + C(C₆H₃Cl₂)), 133.1 (CH, C₅, C₆H₃Cl₂), 131.9 (CH, C₂, C₆H₃Cl₂), 130.8 (CH, C_p, Ph), 129.1 (2CH, C_o, Ph), 128.4 (2CH, C_m, Ph), 127.8 (CH, C_{vinyl}). HRMS (ESI⁺) [*m/z*]: calcd for [C₁₆H₉Cl₂NNaO₂S]⁺ = [M + Na]⁺, 355.9665; found, 355.9664. IR (ν, cm⁻¹): 1699 (vs), 1683.

(*Z*)-4-(3,4-Difluorobenzylidene)-2-phenyl-5(4*H*)-thiazolone **2o**. Thiazolone **2o** was obtained following the same experimental procedure than the described for **2d**. Therefore, oxazolone **1o** (2.5 g, 8.8 mmol) was reacted with thioacetic acid (2 mL) and NEt₃ (0.1 mL) for 18 h at 70 °C to give **2o** as a yellow solid. Obtained: 0.98 g (37% yield). ¹H NMR (CDCl₃, 300.13 MHz): 8.43 (ddd, 1H, H₂, C₆H₃F₂, ³J_{FH} = 11.7 Hz, ⁴J_{FH} = 8.0 Hz, ⁴J_{HH} = 1.9 Hz), 8.04 (d, 2H, H_o, Ph, ³J_{HH} = 6.7 Hz), 7.81 (m, 1H, H₅, C₆H₃F₂), 7.63–7.54 (m, 3H, H_p + 2H_m, Ph), 7.28 (t, 1H, H₆, C₆H₃F₂, ³J_{HH} ≈ ⁴J_{FH} = 8.5 Hz), 7.15 (s, 1H, H_{vinyl}). ¹⁹F NMR (CDCl₃, 282.40 MHz): δ = -131.30 (dddd, 1F, F₄, ³J_{FF} = 21.0 Hz, ³J_{FH} = 14.1 Hz, ⁴J_{FH} = 8.0 Hz, ⁴J_{FH} = 6.0 Hz), -135.95 (ddd, 1F, F₃, ³J_{FF} = 21.0 Hz, ³J_{FH} = 14.1 Hz, ⁴J_{FH} = 6.0 Hz). ¹³C{¹H} NMR (CDCl₃, 75.5 MHz): δ = 194.2 (CO), 168.1 (NCS), 152.2 (dd, C, C₃/C₄, C₆H₃F₂, ¹J_{CF} = 272 Hz, ²J_{CF} = 13.3 Hz), 150.2 (dd, C, C₃/C₄, C₆H₃F₂, ¹J_{CF} = 272 Hz, ²J_{CF} = 13.3 Hz), 146.5 (=C), 133.2 (C, C_p, Ph), 133.0 (CH, C_p, Ph), 131.0 (dd, C, C_i, C₆H₃F₂, ³J_{CF} = 4.1 Hz), 130.2 (dd, CH, C₅, C₆H₃F₂, ²J_{CF} = 6.6 Hz, ³J_{CF} = 3.4 Hz), 129.1 (2CH, C_m, Ph), 128.4 (2CH, C_o, Ph), 128.3 (CH, C_{vinyl}), 121.1 (d, CH, C₂, C₆H₃F₂, ²J_{CF} = 18.7 Hz), 117.7 (d, CH, C₆, C₆H₃F₂, ²J_{CF} = 17.8 Hz). HRMS (ESI⁺) [*m/z*]: calcd for [C₁₆H₁₀F₂NOS]⁺ = [M + H]⁺, 302.0445; found, 302.0446.

General Procedure for the [2 + 2]-Photocycloaddition of 4-Arylidene-2-phenyl-5(4*H*)-thiazolones 2: Synthesis of Cyclobutanes 3a–3o. A solution of the 4-arylidene-2-phenyl-5(4*H*)-thiazolones **2a–2o** (~1 mmol) in 10 mL of CH₂Cl₂ was irradiated for 24–72 h with the blue light (465 nm) provided by the PCB of 24 LEDs while stirred at room temperature. The progress of the reaction was followed by ¹H NMR. After 72 h, the conversion of thiazolones **2a–2o** into cyclobutanes **3a–3o** was complete (exceptions are indicated). The solvent was then evaporated to dryness, and the yellow solid residue was characterized by NMR as the cyclobutanes **3a–3o**. In almost all cases, the *ε*-isomer appeared as the major isomer (>90% molar ratio) with minor amounts (<10%) of other isomers (exceptions are indicated). For that reason, only the *ε*-isomer is fully characterized.



Numbering of Cyclobutanes 3a–3o, Exemplified with 3a. 2,6,9,12-Tetraphenyl-3,10-dithia-1,8-diazadispiro[4.1.4^{7.15}]dodeca-1,8-diene-4,11-dione **3a**. Following the general method, thiazolone **2a** (300 mg, 1.13 mmol) was reacted in CH₂Cl₂ with blue light for 24 h to give **3a** as a yellow solid. Compound **3a** was recrystallized in a mixture CH₂Cl₂/*n*-pentane, the *ε*-isomer was obtained selectively. Obtained: 245.4 mg (82% yield). ¹H NMR (CDCl₃, 300.13 MHz): δ = 7.90 (m, 2H, H_o, NCS-Ph), 7.54–7.48

(m, 5H, H_m, H_p, NCS-Ph; H_o, Ph), 7.20–7.12 (m, 3H, H_m, H_p, Ph), 4.71 (s, 1H, CH₂-C(6,12)). ¹³C{¹H} NMR (CDCl₃, 75.5 MHz): δ = 208.0 (SC = O, C₄,11), 164.9 (SC = N, C₂,9), 133.6 (C_i, Ph), 132.7 (C_i, Ph), 132.3 (C_p, CH, Ph), 131.1 (CH, Ph), 129.0 (CH, Ph), 128.5 (C_o, CH, C₂,9-Ph), 128.2 (C_p, CH, Ph), 128.0 (CH, Ph), 91.3 (C_q, C₅,7), 58.5 (CH, C₆,12). HRMS (ESI⁺) [*m/z*]: calcd for [C₃₂H₂₃N₂O₂S₂]⁺ = [M + H]⁺, 531.1195; found 531.1203.

2,9-Diphenyl-6,12-di-*p*-tolyl-3,10-dithia-1,8-diazadispiro-[4.1.4^{7.15}]dodeca-1,8-diene-4,11-dione 3b. Following the general method, thiazolone **2b** (300 mg, 1.07 mmol) was reacted in CH₂Cl₂ with blue light for 72 h to give **3b** as a yellow solid. Cyclobutane **3b** was obtained as a mixture of two isomers in 90:10 molar ratio. Obtained: 300 mg (100% yield). Only the major *ε*-isomer was fully characterized. ¹H NMR (CD₂Cl₂, 300.13 MHz): δ = 7.98 (m, 2H, H_o, Ph), 7.59 (m, 3H, H_m, H_p, Ph), 7.41 (AA'BB' spin system, 2H, H_o, C₆H₄), 7.02 (AA'BB' spin system, 2H, H_m, C₆H₄), 4.65 (s, 1H, H-C₆,12), 2.21 (s, 3H, CH₃). ¹³C{¹H} NMR (CD₂Cl₂, 75.5 MHz): δ = 207.8 (SC = O, C₄,11), 164.6 (SC = N, C₂,9), 137.9 (C-CH₃), 133.3 (C_i, Ph), 132.2 (C_p, Ph), 130.6 (2C, C_m, C₆H₄), 129.6 (C_i, C₆H₄), 128.9 (2C, C_m, Ph), 128.4 (2C, C_o, C₆H₄), 128.3 (2C, C_o, Ph), 91.2 (C_q, C₅,7), 58.1 (CH, C₆,12), 20.7 (CH₃). HRMS (ESI⁺) [*m/z*]: calcd for [C₃₄H₂₆N₂NaO₂S₂]⁺ = [M + Na]⁺, 581.1333; found, 581.1329.

6,12-Bis(4-methoxyphenyl)-2,9-diphenyl-3,10-dithia-1,8-diazadispiro-[4.1.4^{7.15}]dodeca-1,8-diene-4,11-dione 3c. Following the general method, thiazolone **2c** (300 mg, 1.01 mmol) was reacted in CH₂Cl₂ with blue light for 72 h to give **3c** as a yellow solid. Cyclobutane **3c** was obtained as a mixture of four isomers in 59:25:9:7 molar ratio. Obtained: 300 mg (100% yield). Only the major *ε*-isomer was fully characterized. ¹H NMR (CD₂Cl₂, 300.13 MHz): δ = 7.99 (m, 2H, H_o, Ph), 7.60–7.58 (m, 3H, H_m, H_p, Ph), 7.52 (AA'BB' spin system, 2H, H_o, C₆H₄), 6.75 (AA'BB' spin system, 2H, H_m, C₆H₄), 4.64 (s, 1H, H-C₆,12), 3.69 (s, 3H, -OCH₃). ¹³C{¹H} NMR (CD₂Cl₂, 75.5 MHz): δ = 207.8 (SC = O, C₄,11), 164.6 (SC = N, C₂,9), 159.4 (C-OCH₃), 133.4 (C_i, Ph), 132.3 (2C, C_o, C₆H₄), 131.9 (C_p, Ph), 128.9 (2C, C_m, Ph), 128.2 (2C, C_o, Ph), 124.7 (C_i, C₆H₄), 113.0 (2C, C_m, C₆H₄), 91.7 (C_q, C₅,7), 57.9 (CH, C₆,12), 55.0 (OCH₃). HRMS (ESI⁺) [*m/z*]: calcd for [C₃₄H₂₆N₂NaO₄S₂]⁺ = [M + Na]⁺, 613.1232; found, 613.1237.

6,12-Bis(4-fluorophenyl)-2,9-diphenyl-3,10-dithia-1,8-diazadispiro-[4.1.4^{7.15}]dodeca-1,8-diene-4,11-dione 3d. Following the general method, thiazolone **2d** (300 mg, 1.06 mmol) was reacted in CH₂Cl₂ with blue light for 72 h to give **3d** as a yellow solid. Cyclobutane **3d** was obtained as a mixture of two isomers in 91:9 molar ratio. Obtained: 298 mg (99% yield). Only the major *ε*-isomer was fully characterized. ¹H NMR (CD₂Cl₂, 300.13 MHz): δ = 7.97 (m, 2H, H_o, Ph), 7.63–7.55 (m, 2H, H_o, C₆H₄ + 2H, H_m, Ph + 1H, H_p, Ph), 6.92 (t, 2H, H_m, C₆H₄, ³J_{HH} = ³J_{FH} = 8.73 Hz), 4.69 (s, 1H, H-C₆,12). ¹³C{¹H} NMR (CD₂Cl₂, 75.5 MHz): δ = 207.3 (SC = O, C₄,11), 165.5 (SC = N, C₂,9), 162.5 (d, C-F, ¹J_{FC} = 247 Hz), 133.2 (C_i, C₆H₄), 132.9 (d, 2C, C_o, C₆H₄, ³J_{FC} = 8.3 Hz), 132.5 (C_p, Ph), 129.0 (2C, C_m, Ph), 128.4 (C_i, Ph), 128.2 (2C, C_o, Ph), 114.6 (d, 2C, C_m, C₆H₄, ²J_{FC} = 21.3 Hz), 90.9 (C_q, C₅,7), 57.4 (CH, C₆,12). ¹⁹F NMR (CD₂Cl₂, 282.4 MHz) δ = -114.13 (tt, ³J_{FH} = 8.68 Hz, ⁴J_{FH} = 3.36 Hz). HRMS (ESI⁺) [*m/z*]: calcd for [C₃₂H₂₀F₂N₂NaO₂S₂]⁺ = [M + Na]⁺, 589.0826; found, 589.0812.

6,12-Bis(4-chlorophenyl)-2,9-diphenyl-3,10-dithia-1,8-diazadispiro-[4.1.4^{7.15}]dodeca-1,8-diene-4,11-dione 3e. Following the general method, thiazolone **2e** (300 mg, 1.00 mmol) was reacted in CH₂Cl₂ with blue light for 72 h to give **3e** as a yellow solid. Cyclobutane **3e** was obtained as a mixture of two isomers in a 96:4 molar ratio. Obtained: 255 mg (85% yield). Only the major *ε*-isomer was fully characterized. ¹H NMR (CDCl₃, 500.13 MHz): δ = 7.89 (m, 2H, H_o, Ph), 7.59–7.52 (m, 3H, H_m+H_p, Ph), 7.47 (m, 2H, H_o, C₆H₄), 7.14 (m, 2H, H_m, C₆H₄), 4.63 (s, 1H, H-C₆,12). ¹³C{¹H} NMR (CDCl₃, 125.76 MHz): δ = 207.3 (SC = O, C₄,11), 165.6 (SC = N, C₂,9), 134.3 (C-Cl, C₆H₄), 133.2 (C_i, Ph), 132.5 (C_p, Ph), 132.4 (2C, C_o, C₆H₄), 130.7 (C_i, C₆H₄), 129.0 (2C, C_m, Ph), 128.3 (2C, C_o, Ph), 128.1 (2C, C_m, C₆H₄), 90.7 (C_q, C₅,7), 57.5 (CH, C₆,12).

HRMS (ESI⁺) [*m/z*]: calcd for [C₃₂H₂₀Cl₂N₂NaO₂S₂]⁺ = [M + Na]⁺, 621.0241; found, 621.0233.

6,12-Bis(4-bromophenyl)-2,9-diphenyl-3,10-dithia-1,8-diazadispiro-[4.1.4⁷.1⁵]dodeca-1,8-diene-4,11-dione 3f. Following the general method, thiazolone **2f** (300 mg, 0.87 mmol) was reacted in CH₂Cl₂ with blue light for 72 h to give **3f** as a yellow solid. Cyclobutane **3f** was obtained as a mixture of two isomers in 83:17 molar ratio. Obtained: 276 mg (92% yield). Only the major *ε*-isomer was fully characterized. ¹H NMR (CDCl₃, 300.13 MHz): δ = 7.89 (m, 2H, H_o, Ph), 7.57–7.51 (m, 3H, H_m + H_p, Ph), 7.41 (m, 2H, H_o, C₆H₄), 7.30 (m, 2H, H_m, C₆H₄), 4.63 (s, 1H, H-C6,12). ¹³C{¹H} NMR (CDCl₃, 75.5 MHz): δ = 207.3 (SC = O, C₄,11), 165.8 (SC = N, C₂,9), 133.3 (C_p, Ph), 132.8 (2C, C_o, C₆H₄), 132.6 (C_p, Ph), 131.4 (C_p, C₆H₄), 131.2 (2C, C_m, C₆H₄), 129.2 (2C, C_m, Ph), 128.4 (2C, C_o, Ph), 122.8 (Br-C_p, C₆H₄), 90.7 (C_q, C5,7), 57.7 (CH, C6,12). Anal. Calcd for C₁₆H₁₀BrNOS: C, 55.83; H, 2.93; N, 4.07; S, 9.31. Found: C, 56.18; H, 2.63; N, 4.08; S, 9.67.

6,12-Bis(4-nitrophenyl)-2,9-diphenyl-3,10-dithia-1,8-diazadispiro-[4.1.4⁷.1⁵]dodeca-1,8-diene-4,11-dione 3g. Following the general method, thiazolone **2g** (300 mg, 0.94 mmol) was reacted in CH₂Cl₂ with blue light for 72 h to give **3g** as a yellow solid. Cyclobutane **3g** was obtained as a single isomer (*ε*-isomer). Obtained: 298 mg (100% yield). ¹H NMR (CD₂Cl₂, 300.13 MHz): δ = 8.06 (m, 2H, H_m, C₆H₄), 7.95 (m, 2H, H_o, Ph), 7.77 (m, 2H, H_o, C₆H₄), 7.65–7.56 (m, 3H, H_p + H_m, Ph), 4.84 (s, 1H, H-C6,12). ¹³C{¹H} NMR (CD₂Cl₂, 75.5 MHz): δ = 206.5 (SC = O, C₄,11), 167.0 (SC = N, C₂,9), 147.7 (C₆H₄, C-NO₂), 139.2 (C_p, C₆H₄), 132.9 (C_p, Ph), 132.7 (C_p, Ph), 131.9 (2C, C_o, C₆H₄), 129.1 (2C, C_m, Ph), 128.3 (2C, C_o, Ph), 122.9 (2C, C_m, C₆H₄), 89.7 (C_q, C5,7), 57.1 (CH, C6,12). HRMS (ESI⁺) [*m/z*]: calcd for [C₃₂H₂₀N₄NaO₆S₂]⁺ = [M + Na]⁺, 643.0716; found, 643.0708.

6,12-Bis(4-trifluoromethylphenyl)-2,9-diphenyl-3,10-dithia-1,8-diazadispiro-[4.1.4⁷.1⁵]dodeca-1,8-diene-4,11-dione 3h. Following the general method, thiazolone **2h** (300 mg, 0.90 mmol) was reacted in CH₂Cl₂ with blue light for 72 h to give a maximal conversion of **3h** of 80% as a single isomer (*ε*-isomer). Further irradiation of the solution did not improve the conversion. Obtained: 241 mg. The remaining thiazolone **2h** proved to be difficult to be separated. ¹H NMR (CDCl₃, 500.13 MHz): δ = 7.89 (m, 2H, H_o, Ph), 7.63 (m, 2H, H_o, C₆H₄), 7.60–7.53 (m, 3H, H_p + H_m, Ph), 7.44 (m, 2H, H_m, C₆H₄), 4.75 (s, 1H, H-C6,12). ¹³C{¹H} NMR (CDCl₃, 125.7 MHz): δ = 207.1 (SC = O, C₄,11), 166.3 (SC = N, C₂,9), 136.2 (C_p, C₆H₄), 133.1 (C_p, Ph), 132.8 (C_p, Ph), 131.4 (2C, C_o, C₆H₄), 130.5 (q, C-CF₃, ²J_{CF} = 66.6 Hz), 129.3 (2C, C_m, Ph), 128.4 (2C, C_o, Ph), 125.0 (q, 2C, C_m, C₆H₄, ³J_{CF} = 3.7 Hz), 124.0 (q, CF₃, ¹J_{CF} = 272.2 Hz), 90.5 (C_q, C5,7), 57.7 (CH, C6,12). ¹⁹F NMR (CDCl₃, 282 MHz) δ = -62.72 (s, CF₃). HRMS (ESI⁺) [*m/z*]: calcd for [C₃₄H₂₀F₆N₂NaO₂S₂]⁺ = [M + Na]⁺, 689.0752; found, 689.0768.

6,12-Bis(2-chlorophenyl)-2,9-diphenyl-3,10-dithia-1,8-diazadispiro-[4.1.4⁷.1⁵]dodeca-1,8-diene-4,11-dione 3j. Following the general method, thiazolone **2j** (300 mg, 1.00 mmol) was reacted in CH₂Cl₂ with blue light for 72 h to give **3j** as a yellow solid. Cyclobutane **3j** was obtained as the mixture of two isomers in 71:29 molar ratio. Obtained: 285 mg (95% yield). Only the major *ε*-isomer was fully characterized. ¹H NMR (CDCl₃, 500.13 MHz): δ = 8.19 (dd, 1H, H_o, C₆H₄, ³J_{HH} = 7.0 Hz, ⁴J_{HH} = 2.3 Hz), 7.87 (m, 2H, H_o, Ph), 7.58–7.46 (m, 3H, H_m+H_p, Ph, overlapped with minor isomer), 7.24 (dd, 1H, H₃, C₆H₄, ³J_{HH} = 7.0 Hz, ⁴J_{HH} = 1.9 Hz), 7.06 (td, 2H, H₄, H₅, C₆H₄, ³J_{HH} = 7.0 Hz, ⁴J_{HH} = 1.9 Hz), 5.54 (s, 1H, H-C6,12). ¹³C{¹H} NMR (CDCl₃, 125.7 MHz): δ = 206.3 (SC = O, C₄,11), 165.6 (SC = N, C₂,9), 134.9 (C_p, C₆H₄), 134.0 (C_o, C₆H₄), 133.4 (C_p, Ph), 132.3 (C_p, Ph), 130.4 (C₂, C₆H₄), 129.2, 125.8 (2C, C₄, C₅, C₆H₄), 129.1 (C₃, C₆H₄), 128.9 (2C, C_m, Ph), 128.2 (2C, C_o, Ph), 90.4 (C_q, C5,7), 53.0 (CH, C6,12). HRMS (ESI⁺) [*m/z*]: calcd for [C₃₂H₂₀Cl₂N₂NaO₂S₂]⁺ = [M + Na]⁺, 621.0241; found, 621.0238.

6,12-Bis(2-bromophenyl)-2,9-diphenyl-3,10-dithia-1,8-diazadispiro-[4.1.4⁷.1⁵]dodeca-1,8-diene-4,11-dione 3k. Following the general method, thiazolone **2k** (300 mg, 0.87 mmol) was reacted in CH₂Cl₂ with blue light for 72 h to give **3k** as a yellow solid. Cyclobutane **3k** was obtained as the mixture of two isomers in 65:35

molar ratio. Obtained: 295 mg (98% yield). In this case, well-separated peaks were observed for the two isomers, allowing their full characterization. Major isomer (*ε*-isomer) ¹H NMR (CDCl₃, 500.13 MHz): δ = 8.32 (dd, 1H, H₆, C₆H₄, ³J_{HH} = 8.1 Hz, ⁴J_{HH} = 1.7 Hz), 7.87 (m, 2H, H_o, Ph), 7.58–7.48 (m, 3H, H_p+H_m, Ph; overlapped with minor isomer), 7.43 (dd, 1H, H₃, C₆H₄, ³J_{HH} = 7.9 Hz, ⁴J_{HH} = 1.2 Hz), 7.14 (td, 1H, H₅, C₆H₄, ³J_{HH} = 7.8 Hz, ⁴J_{HH} = 1.3 Hz), 6.97 (td, 1H, H₄, C₆H₄, ³J_{HH} = 7.8 Hz, ⁴J_{HH} = 1.7 Hz), 5.62 (s, 1H, H-C6,12). ¹³C{¹H} NMR (CDCl₃, 125.76 MHz): δ = 206.2 (SC = O, C₄,11), 165.6 (SC = N, C₂,9), 134.5 (C₆, C₆H₄), 133.4 (C_p, Ph), 132.5 (C₃, C₆H₄), 132.3 (C_p, Ph), 132.1 (C_p, C₆H₄), 129.5 (C₄, C₆H₄), 128.9 (2C, C_m, Ph; overlapped with minor isomer), 128.2 (2C, C_o, Ph), 126.4 (C₅, C₆H₄), 125.9 (Br-C₂, C₆H₄), 90.5 (C_q, C5,7), 55.4 (CH, C6,12). Minor isomer (*α*-isomer) ¹H NMR (CDCl₃, 500.13 MHz): δ = 8.62 (dd, H₆, C₆H₄, ³J_{HH} = 8.0 Hz, ⁴J_{HH} = 2.2 Hz), 7.96 (m, H_o, Ph), 7.58–7.48 (m, H_p+H_m, Ph; overlapped with major isomer), 7.46 (dd, 1H, H₃, C₆H₄, ³J_{HH} = 8.0 Hz, ⁴J_{HH} = 1.1 Hz), 7.35 (td, 1H, H₅, C₆H₄, ³J_{HH} = 7.7 Hz, ⁴J_{HH} = 1.3 Hz), 7.09 (td, 1H, H₄, C₆H₄, ³J_{HH} = 7.8 Hz, ⁴J_{HH} = 1.7 Hz), 5.91 (s, 1H, H-C6,12). ¹³C{¹H} NMR (CDCl₃, 125.76 MHz): δ = 205.8 (SC = O, C₄,11), 164.9 (SC = N, C₂,9), 134.0 (C₆, C₆H₄), 133.5 (C_p, Ph), 133.3 (C_p, C₆H₄), 132.6 (C₃, C₆H₄), 132.3 (C_p, Ph), 129.5 (C₄, C₆H₄), 128.9 (2C, C_m, Ph, overlapped), 128.5 (2C, C_o, Ph), 127.0 (C₅, C₆H₄), 125.4 (Br-C₂, C₆H₄), 88.7 (C_q, C5,7), 54.9 (CH, C6,12). Anal. Calcd for C₁₆H₁₀BrNOS: C, 55.83; H, 2.93; N, 4.07; S, 9.31. Found: C, 55.79; H, 2.91; N, 4.05; S, 9.62.


6,12-Bis(3,4-dimethylphenyl)-2,9-diphenyl-3,10-dithia-1,8-diazadispiro-[4.1.4⁷.1⁵]dodeca-1,8-diene-4,11-dione 3m. Following the general method, thiazolone **2m** (300 mg, 1.02 mmol) was reacted in CH₂Cl₂ with blue light for 72 h to give **3m** as a yellow solid. Cyclobutane **3m** was obtained as the mixture of two isomers in 85:15 molar ratio. Obtained: 299 mg (100% yield). Only the major *ε*-isomer was fully characterized. ¹H NMR (CDCl₃, 500.13 MHz): δ = 7.93 (m, 2H, H_o, Ph), 7.55–7.49 (m, 3H, H_p+H_m, Ph), 7.34–7.28 (m, 2H, H₂ + H₆, C₆H₃), 6.91 (d, 1H, H₅, C₆H₃, ³J_{HH} = 7.83 Hz), 4.61 (s, 1H, H-C6,12), 2.11 (s, 3H, C₃-Me), 2.09 (s, 3H, C₄-Me). ¹³C{¹H} NMR (CDCl₃, 125.76 MHz): δ = 208.0 (SC = O, C₄,11), 164.2 (SC = N, C₂,9), 136.4 (C₁, C₆H₃), 135.7 (C₄, C₆H₃), 133.7 (C_p, Ph), 132.5 (C₂, C₆H₃), 132.0 (C_p, Ph), 130.0 (C₃, C₆H₃), 129.0 (C₅, C₆H₃), 128.8 (2C, C_m, Ph), 128.6 (C₆, C₆H₃), 128.3 (2C, C_o, Ph), 91.6 (C_q, C5,7), 58.3 (CH, C6,12), 19.7 (C₃-Me), 19.4 (C₄-Me). HRMS (ESI⁺) [*m/z*]: calcd for [C₃₆H₃₀N₂NaO₂S₂]⁺ = [M + Na]⁺, 609.1646; found, 609.1651.

6,12-Bis(3,4-dichlorophenyl)-2,9-diphenyl-3,10-dithia-1,8-diazadispiro-[4.1.4⁷.1⁵]dodeca-1,8-diene-4,11-dione 3n. Following the general method, thiazolone **2n** (300 mg, 0.90 mmol) was reacted in CH₂Cl₂ with blue light for 72 h to give **3n** as a yellow solid. Cyclobutane **3n** was obtained as the mixture of two isomers in 91:9 molar ratio. Obtained: 298 mg (100% yield). Only the major *ε*-isomer was fully characterized. ¹H NMR (CD₂Cl₂, 300.13 MHz): δ = 7.99 (m, 2H, H_o, Ph), 7.91 (d, 1H, H₂, C₆H₃, ⁴J_{HH} = 2.0 Hz), 7.66–7.56 (m, 3H, H_p+H_m, Ph), 7.42 (dd, 1H, H₆, C₆H₃, ³J_{HH} = 8.4 Hz, ⁴J_{HH} = 2.1 Hz), 7.29 (d, 1H, H₅, C₆H₃, ³J_{HH} = 8.4 Hz), 4.62 (s, 1H, H-C6,12). ¹³C{¹H} NMR (CD₂Cl₂, 75.5 MHz): δ = 206.7 (SC = O, C₄,11), 166.6 (SC = N, C₂,9), 133.6 (C₂, C₆H₃), 132.8 (C_p, Ph), 132.4 (C₄, C₆H₃), 132.2 (2C, C₁ (Ph)+C₁ (C₆H₃)), 131.6 (C₃, C₆H₃), 130.6 (C₆, C₆H₃), 129.7 (C₅, C₆H₃), 129.1 (2C, C_m, Ph), 128.3 (2C, C_o, Ph), 89.9 (C_q, C5,7), 56.7 (CH, C6,12). HRMS (ESI⁺) [*m/z*]: calcd for [C₃₂H₁₈Cl₂N₂NaO₂S₂]⁺ = [M + Na]⁺, 688.9461; found, 688.9466.

6,12-Bis(3,4-difluorophenyl)-2,9-diphenyl-3,10-dithia-1,8-diazadispiro-[4.1.4⁷.1⁵]dodeca-1,8-diene-4,11-dione 3o. Following the general method, thiazolone **2o** (300 mg, 1.00 mmol) was reacted in CH₂Cl₂ with blue light for 72 h to give **3o** as a yellow solid. Cyclobutane **3o** was obtained as the mixture of two isomers in 94:6 molar ratio. Obtained: 271 mg (90% yield). Only the major *ε*-isomer was fully characterized. ¹H NMR (CDCl₃, 500.13 MHz): δ = 7.91 (m, 2H, H_o, Ph), 7.65 (td, 1H, H₆, C₆H₃, ³J_{HH} = ⁴J_{HF} = 9.5 Hz, ⁴J_{HH} = 2.2 Hz), 7.61–7.53 (m, 3H, H_p + H_m, Ph), 7.12 (dt, 1H, H₂, C₆H₃, ³J_{HF} = 8.7 Hz, ⁴J_{HH} = 2.2 Hz), 6.94 (q, 1H, H₅, C₆H₃, ³J_{HF} = ⁴J_{HF} = ³J_{HH} = 9.5 Hz), 4.59 (s, 1H, H-C6,12). ¹³C{¹H} NMR (CDCl₃, 125.76

MHz): δ = 206.9 (SC = O, C₄,11), 166.3 (SC = N, C₂,9), 150.4 (dd, C₄-F, $^1J_{CF}$ = 253.2 Hz, $^2J_{CF}$ = 14.7 Hz), 149.5 (dd, C₃-F, $^1J_{CF}$ = 249.6 Hz, $^2J_{CF}$ = 15.3 Hz), 132.9 (C₉, Ph), 132.7 (C₉, Ph), 129.2 (2C, C₁₀, Ph), 128.9 (m, C₁, C₆H₃), 128.3 (2C, C₁₀, Ph), 127.1 (t, C₂, C₆H₃, $^2J_{CF}$ = $^3J_{CF}$ = 5.3 Hz), 120.7 (t, C₆, C₆H₃, $^2J_{CF}$ = $^3J_{CF}$ = 10.06 Hz), 116.6 (dd, C₅, C₆H₃, $^2J_{FC}$ = 14.13 Hz, $^3J_{CF}$ = 3.64 Hz), 90.5 (C₉, C₅,7), 56.8 (CH, C₆,12). $^{19}\text{F}\{^1\text{H}\}$ NMR (CDCl₃, 282.4 MHz) δ = -137.37 (d, $^3J_{FF}$ = 9.6 Hz), -137.33 (d, $^3J_{FF}$ = 9.6 Hz). HRMS (ESI⁺) [*m/z*]: calcd for [C₃₂H₁₈F₄N₂NaO₂S₂]⁺ = [M + Na]⁺, 625.0644; found, 625.0640.

General Procedure for the [2 + 2]-Photocycloaddition of 4-Arylidene-2-phenyl-5(4H)-thiazolones 2 in the Presence of BF₃: Synthesis of Cyclobutanes 4a–4e. To a suspension of the thiazolones 2a–2e (around 0.38 mmol) in dry deoxygenated methanol (3 mL) under an Ar atmosphere, BF₃·OEt₂ was added (200 μ L, 1.621 mmol). The resulting suspension was irradiated for 24 h with the blue light provided by a Kessil lamp (PR160L, 40 W). The distance between the sample and the lamp is 5 cm, and the power of the lamp is fixed at 50% to avoid the overheating of the sample. After the reaction time, the solid in suspension is filtered, washed with MeOH, dried in vacuo, and characterized as cyclobutanes 4a–4e.



Numbering of Cyclobutanes 4a–4e, Exemplified with 4a. Methyl 8-Oxo-1,3,6-triphenyl-2-phenylthioamido-7-thia-5-azaspiro[3.4]oct-5-ene-2-carboxylate 4a. Following the general method, thiazolone 2a (299.6 mg, 1.13 mmol) and BF₃·OEt₂ (600 μ L, 4.863 mmol) were irradiated with blue light (456 nm) for 24 h in dry and deoxygenated methanol (9 mL) to give cyclobutane 4a as a pale-yellow solid. Obtained: 185.1 mg (59% yield). ^1H NMR (CDCl₃, 300.13 MHz): δ = 8.66 (s, 1H, NH), 7.68 (d, 2H, H₉, NCS-Ph), 7.65 (m, 2H, H₉, NCS-Ph), 7.54 (t, 1H, H₉, NCS-Ph), 7.50–7.42 (m, 3H, H₉, H₁₀, NCS-Ph), 7.42–7.33 (m, 6H, H₁₀, NCS-Ph, H₁₀, Ph), 7.24–7.15 (m, 6H, H₁₀, H₁₀, Ph), 4.94 (s, 2H, H-C1,3), 3.88 (s, 3H, OMe). $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl₃, 75.5 MHz): δ = 206.3 (SC = O, C₈), 199.0 (NC = S, C₉), 169.7 (COO), 166.5 (SC = N, C₆), 141.2 (C₉, C₆-Ph), 133.0 (C₉, C₉-Ph), 132.7 (C₉, CH, C₆-Ph), 132.5 (C₉, C₁,3-Ph), 131.4 (C₉, CH, C₉-Ph), 129.5 (C₉, CH, C₁,3-Ph), 129.2 (C₉, CH, C₁,3-Ph), 128.7 (C₉, CH, C₆-Ph), 128.7 (C₉, CH, C₁,3-Ph), 128.2 (C₉, CH, C₉-Ph), 128.2 (C₉, CH, C₆-Ph), 126.5 (C₉, CH, C₉-Ph), 90.8 (C₉, C₄), 67.8 (C₉, C₂), 55.0 (CH, C₁,3), 53.1 (OMe). HRMS (ESI⁺) [*m/z*]: calcd for [C₃₃H₂₇N₂O₃S₂]⁺ = [M + H]⁺, 563.1463; found, 563.1457.

Methyl 8-Oxo-6-phenyl-2-phenylthioamido-1,3-di-p-tolyl-7-thia-5-azaspiro[3.4]oct-5-ene-2-carboxylate 4b. Following the general method, thiazolone 2b (99.84 mg, 0.358 mmol) and BF₃·OEt₂ (200 μ L, 1.621 mmol) were irradiated with blue light (456 nm) for 24 h in dry and deoxygenated methanol (3 mL) to give cyclobutane 4b as a yellow solid. Compound 4b was recrystallized from CH₂Cl₂/*n*-pentane. Obtained: 41.1 mg (39% yield). ^1H NMR (CDCl₃, 300.13 MHz): δ = 8.64 (s, 1H, NH), 7.72 (m, 2H, H₉, NCS-Ph), 7.68 (m, 2H, H₉, NCS-Ph), 7.55 (m, 1H, H₉, NCS-Ph), 7.50–7.43 (m, 3H, H₉, H₁₀, NCS-Ph), 7.37 (t, 2H, H₁₀, NCS-Ph), 7.27 (d, 4H, H₁₀, C₆H₄Me, $^3J_{HH}$ = 7.7 Hz), 7.00 (d, 4H, H₁₀, C₆H₄Me, $^3J_{HH}$ = 7.7 Hz), 4.87 (s, 2H, H-C1,3), 3.86 (s, 3H, OMe), 2.24 (s, 6H, Me). $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl₃, 75.5 MHz): δ = 206.5 (SC = O, C₈), 198.9 (NC = S, C₉), 169.8 (COO), 166.1 (SC = N, C₆), 141.4 (C₉, C₆/C₉-Ph), 138.5 (C₉, C₁,3-C₆H₄Me), 138.0 (C₉, C₁,3-C₆H₄Me), 133.1 (C₉, C₆/C₉-Ph), 132.6 (C₉, CH, C₆/C₉-Ph), 131.3 (C₉, CH, C₆/C₉-Ph), 129.4 (C₉, C₁,3-C₆H₄), 129.4 (C₉, C₁,3-C₆H₄), 129.2 (C₉, CH, C₆/C₉-Ph), 128.7 (C₉, CH, C₆/C₉-Ph), 128.2 (C₉, CH, C₆/C₉-Ph), 126.6 (C₉, CH, C₆/C₉-Ph), 91.1 (C₉, C₄), 67.8 (C₉, C₂), 54.9 (CH,

C₁,3), 53.0 (OMe), 21.3 (Me). HRMS (ESI⁺) [*m/z*]: calcd for [C₃₅H₃₀N₂O₃S₂Na]⁺ = [M + Na]⁺, 613.1590; found, 613.1588.

Methyl 1,3-Bis(4-fluorophenyl)-8-oxo-6-phenyl-2-phenylthioamido-7-thia-5-azaspiro[3.4]oct-5-ene-2-carboxylate 4d. Following the general method, thiazolone 2d (100.61 mg, 0.355 mmol) and BF₃·OEt₂ (200 μ L, 1.621 mmol) in dry and deoxygenated methanol (3 mL) were irradiated with blue light (456 nm) for 24 h to give cyclobutane 4d as a yellow solid. Compound 4d was recrystallized from CH₂Cl₂/*n*-pentane. Obtained: 34.99 mg (33% yield). ^1H NMR (CDCl₃, 300.13 MHz): δ = 8.54 (s, 1H, NH), 7.67 (m, 2H, H₉, NCS-Ph), 7.64 (m, 2H, H₉, NCS-Ph), 7.57 (m, 1H, H₉, NCS-Ph), 7.54–7.42 (m, 3H, H₉, H₁₀, NCS-Ph), 7.39 (t, 2H, H₁₀, NCS-Ph), 7.35 (m, 4H, H₁₀, C₆H₄F), 6.90 (t, 4H, H₁₀, C₆H₄F), 4.88 (s, 2H, H-C1,3), 3.88 (s, 3H, OMe). $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl₃, 75.5 MHz): δ = 205.9 (SC = O, C₈), 199.0 (NC = S, C₉), 169.5 (COO), 167.2 (SC = N, C₆), 162.7 (d, C-F, C₁,3-C₆H₄F, $^1J_{FC}$ = 248.21 Hz), 140.9 (C₉, C₆/C₉-Ph), 133.0 (C₉, CH, C₆/C₉-Ph), 132.7 (2C overlapped, C₉, C₆/C₉-Ph + C₉, C₁,3-C₆H₄F), 131.7 (C₉, CH, C₆/C₉-Ph), 131.2 (d, C₉, C₁,3-C₆H₄F, $^3J_{FC}$ = 8.04 Hz), 129.4 (C₉, CH, C₆/C₉-Ph), 128.8 (C₉, CH, C₆/C₉-Ph), 128.1 (C₉, CH, C₆/C₉-Ph), 126.4 (C₉, CH, C₆/C₉-Ph), 115.7 (d, C₉, C₁,3-C₆H₄F, $^2J_{FC}$ = 21.32 Hz), 90.6 (C₉, C₄), 67.7 (C₉, C₂), 54.2 (CH, C₁,3), 53.2 (OMe). ^{19}F NMR (CDCl₃, 282.40 MHz) δ = -113.18 (tt, $^3J_{FH}$ = 8.8 Hz, $^4J_{FH}$ = 3.7 Hz). HRMS (ESI⁺) [*m/z*]: calcd for [C₃₃H₂₅F₂N₂O₃S₂]⁺ = [M + H]⁺, 599.1269; found, 599.1262.

Methyl 1,3-Bis(4-chlorophenyl)-8-oxo-6-phenyl-2-phenylthioamido-7-thia-5-azaspiro[3.4]oct-5-ene-2-carboxylate 4e. Following the general method, thiazolone 2e (100.37 mg, 0.336 mmol) and BF₃·OEt₂ (200 μ L, 1.621 mmol) in dry and deoxygenated methanol (3 mL) were irradiated with blue light (456 nm); 100% intensity in this case to maximize the conversion) for 24 h to give cyclobutane 4e as a yellow solid. Compound 4e was recrystallized from CH₂Cl₂/*n*-pentane. Obtained: 32.27 mg (31% yield). ^1H NMR (CDCl₃, 300.13 MHz): δ = 8.53 (s, 1H, NH), 7.67 (m, 2H, H₉, NCS-Ph), 7.64 (m, 2H, H₉, NCS-Ph), 7.57 (m, 1H, H₉, NCS-Ph), 7.53–7.44 (m, 3H, H₉, H₁₀, NCS-Ph), 7.40 (t, 2H, H₁₀, NCS-Ph), 7.29 (d, 4H, H₁₀, C₆H₄Cl, $^3J_{HH}$ = 8.5 Hz), 7.18 (d, 4H, H₁₀, C₆H₄Cl, $^3J_{HH}$ = 8.53 Hz), 4.86 (s, 2H, H-C1,3), 3.88 (s, 3H, OMe). $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl₃, 75.5 MHz): δ = 205.8 (SC = O, C₈), 198.1 (NC = S, C₉), 169.4 (COO), 167.4 (SC = N, C₆), 140.9 (C₉, C₆/C₉-Ph), 134.4 (C₉, C₁,3-C₆H₄Cl), 133.1 (C₉, CH, C₆/C₉-Ph), 131.7 (C₉, CH, C₆/C₉-Ph), 132.6 (C₉, C₆/C₉-Ph), 132.4 (C₉, C₁,3-C₆H₄Cl), 130.7 (C₉, C₁,3-C₆H₄Cl), 129.4 (C₉, CH, C₆/C₉-Ph), 128.9 (C₉, C₁,3-C₆H₄Cl), 128.9 (C₉, CH, C₆/C₉-Ph), 128.1 (C₉, CH, C₆/C₉-Ph), 126.4 (C₉, CH, C₆/C₉-Ph), 90.4 (C₉, C₄), 67.6 (C₉, C₂), 54.3 (CH, C₁,3), 52.2 (OMe). HRMS (ESI⁺) [*m/z*]: calcd for [C₃₃H₂₄Cl₂N₂O₃S₂Na]⁺ = [M + Na]⁺, 653.0498; found, 653.0506.

Synthesis of Dihydrothiazoles (5 and 6) and Thiazoles (7) through a Ring-Opening Reaction Promoted by a Base. Reaction of Cyclobutanes 3c and 3d with NaOMe in MeOH. To a suspension of the cyclobutanes 3c or 3d (150 mg) in methanol (10 mL) was added NaOMe (10 mg). The resulting mixture was heated in an oil bath at 60 °C for 30 min. After the reaction time, the resulting solution was evaporated to dryness, and the residue was extracted with CH₂Cl₂ (2 \times 15 mL). Any insoluble solid in the CH₂Cl₂ was removed by filtration. The organic phase was washed with H₂O (10 mL), dried with anhydrous MgSO₄, and evaporated to dryness, giving dihydrothiazoles 5c or 5d as yellow oils. Obtained: 168 mg (5c, 92% yield); 166 mg (5d, 94% yield). Compounds 5c and 5d were characterized by NMR methods as the mixture of the two possible diastereoisomers *trans* (RR/SS) and *cis* (RS/SR) in *trans/cis* = 86:14 (5c) and 81:19 (5d) molar ratios.

***trans*-(RR/SS) Methyl 5-(4-Methoxyphenyl)-2-phenyl-4,5-dihydrothiazole-4-carboxylate 5c.** ^1H NMR (CDCl₃, 300.13 MHz): δ = 7.92 (d, 2H, H₉, Ph, $^3J_{HH}$ = 7 Hz), 7.52–7.46 (m, 3H, H₉, H₁₀, Ph), 7.35 (AA'BB' spin system, 2H, H₉, C₆H₄), 6.89 (AA'BB' spin system, 2H, H₁₀, C₆H₄), 5.45, 5.35 (AB spin system, 2H, H₄+H₅, $^3J_{HH}$ = 6.6 Hz), 3.83 (s, 3H, CO₂Me), 3.81 (s, 3H, OMe). $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl₃, 75.5 MHz): δ = 170.8 (CO₂Me), 170.4 (SC = N), 159.5 (C₉-OMe, C₆H₄), 132.7, 132.2 (2C, C₁ (C₆H₄ + Ph)), 131.8 (C₉, Ph),

128.7 (C_o, C₆H₄), 128.6 (C_o, Ph), 128.6 (C_m, Ph), 114.3 (C_m, C₆H₄), 86.6 (C₄), 56.3 (C₅), 55.3 (OMe), 52.8 (CO₂Me). HRMS (ESI⁺) [*m/z*]: calcd for [C₁₈H₁₈NO₃S]⁺ = [M + H]⁺, 328.1002; found, 328.1010.

trans-(RR/SS) Methyl 5-(4-Fluorophenyl)-2-phenyl-4,5-dihydrothiazole-4-carboxylate 5d. ¹H NMR (CDCl₃, 300.13 MHz): δ = 7.92 (dd, 2H, H_o, Ph), ³J_{HH} = 6.8 Hz, ⁴J_{HH} = 1.2 Hz), 7.50–7.44 (m, 3H, H_p+H_m, Ph), 7.41 (m, 2H, H_o, C₆H₄), 7.02 (dd, 2H, H_m, C₆H₄, ³J_{HH} = 8.7 Hz, ⁴J_{HH} = 2.4 Hz), 5.46, 5.33 (AB spin system, 2H, H₄+H₅, ³J_{HH} = 6.5 Hz), 3.81 (s, 3H, CO₂Me). ¹³C{¹H} NMR (CDCl₃, 75.5 MHz): δ = 170.6 (CO₂Me), 170.2 (SC = N), 162.4 (d, C_p-F, C₆H₄, ¹J_{CF} = 248.21 Hz), 136.1 (C_v, C₆H₄), 132.5 (C_v, Ph), 131.9 (C_p, Ph), 129.2 (d, C_o, C₆H₄, ³J_{CF} = 8.3 Hz), 128.7 (C_o, Ph), 128.6 (C_m, Ph), 115.9 (d, C_m, C₆H₄, ²J_{CF} = 21.9 Hz), 86.7 (C₄), 55.9 (C₅), 52.9 (CO₂Me). ¹⁹F NMR (CDCl₃, 282 MHz) δ = -113.15 (tt, CF, ³J_{FF} = 8.09 Hz, ⁴J_{FF} = 4.86 Hz). HRMS (ESI⁺) [*m/z*]: calcd for [C₁₇H₁₃FNO₂S]⁺ = [M - H]⁺, 314.0657; found, 314.0649.

General Procedure for the Synthesis of trans-(RR/SS) Ethyl 5-Aryl-2-phenyl-4,5-dihydrothiazole-4-carboxylates 6. All syntheses of *trans*-(RR/SS) ethyl 5-aryl-2-phenyl-4,5-dihydrothiazole-4-carboxylates **6** were performed using the same experimental method, which is detailed here for the synthesis of **6c**. To a suspension of thiazolone **2c** (600 mg, 2.03 mmol) in 10 mL of ethanol was added NaOEt (10 mg, 0.09 mmol). The resulting mixture was refluxed (80 °C) in an oil bath for 2 h, then left to reach room temperature. The resulting solution was evaporated to dryness. The orange oily residue was extracted with CH₂Cl₂ (25 mL), removing all insoluble material by filtration. The clear solution was evaporated to dryness, and the residue was characterized by NMR as the dihydrothiazole **6c** (mixture of the two diastereoisomers), although impure. Therefore, *trans*-(RR/SS)-**6c** (the main component of the mixture) was purified by column chromatography using silica gel as support and a mixture of *n*-hexane/Et₂O (8:1) as an eluent. The band collected under these conditions is *trans*-(RR/SS)-**6c**. Obtained: 411 mg (58% yield).

trans-(RR/SS) Ethyl 5-(4-Methoxyphenyl)-2-phenyl-4,5-dihydrothiazole-4-carboxylate 6c. ¹H NMR (CDCl₃, 300.13 MHz): δ = 7.92 (d, 2H, H_o, Ph), ³J_{HH} = 6.9 Hz), 7.52–7.36 (m, 3H, H_p + H_m, Ph), 7.34 (d, 2H, H₂, H₆, C₆H₄OMe, ³J_{HH} = 8.7 Hz), 6.89 (d, 2H, H₃, H₅, C₆H₄OMe, ³J_{HH} = 8.7 Hz), 5.43 (AB spin system, 1H, SCH, ³J_{HH} = 6.7 Hz), 5.32 (AB spin system, 1H, NCH, ³J_{HH} = 6.7 Hz), 4.29 (q, 2H, OCH₂CH₃, ³J_{HH} = 7.1 Hz), 3.82 (s, 3H, OMe), 1.32 (t, 3H, OCH₂CH₃, ³J_{HH} = 7.1 Hz). ¹³C{¹H} NMR (CDCl₃, 75.5 MHz): δ = 170.3 (CO), 170.3 (NCS), 159.5 (C₄, C₆H₄OMe), 132.8 (C_v, Ph), 132.3 (C₁, C₆H₄OMe), 131.7 (CH, C_p, Ph), 128.7 (CH, C_o, Ph), 128.7 (2CH, C₂+C₆, C₆H₄OMe), 128.6 (2CH, C_m, Ph), 114.3 (2CH, C₃+C₅, C₆H₄OMe), 86.8 (CH, NC4H), 61.8 (CH₂), 56.5 (CH, SC5H), 55.3 (OMe), 14.2 (CH₃). HRMS (ESI⁺) [*m/z*]: calcd for [C₁₉H₁₉NNaO₃S]⁺ = [M + Na]⁺, 364.0983; found, 364.0983.

trans-(RR/SS) Ethyl 5-(4-Trifluoromethylphenyl)-2-phenyl-4,5-dihydrothiazole-4-carboxylate 6h. Following the general procedure, thiazolone **2h** (192 mg, 0.58 mmol) was reacted with NaOEt (10 mg, 0.09 mmol) for 2 h in refluxing EtOH (10 mL) to give, after chromatographic purification using silica gel as support and *n*-hexane/Et₂O (8:1) as an eluent, *trans*-(RR/SS)-**6h** as a waxy orange solid. Obtained: 166.5 mg (76% yield). ¹H NMR (CDCl₃, 300.13 MHz): δ = 7.93 (d, 2H, H_o, Ph), ³J_{HH} = 7.0 Hz), 7.65–7.46 (m, 7H, H_p+H_m, Ph; H_{2,6}+H_{3,5}, C₆H₄CF₃), 5.49 (AB spin system, 1H, SCH, ³J_{HH} = 6.3 Hz), 5.36 (AB spin system, 1H, NCH, ³J_{HH} = 6.3 Hz), 4.31 (q, 2H, OCH₂CH₃, ³J_{HH} = 7.1 Hz), 3.87 (s, 3H, OMe), 1.33 (t, 3H, OCH₂CH₃, ³J_{HH} = 7.1 Hz). ¹³C{¹H} NMR (CDCl₃, 75.5 MHz): δ = 170.3 (NCS), 169.8 (CO), 144.4 (C₁, C₆H₄CF₃), 132.3 (C_v, Ph), 132.1 (C_p, Ph), 130.4 (q, C₄-CF₃, ²J_{CF} = 40 Hz), 128.8 (C_o, Ph), 128.7 (C_m, Ph), 128.0 (C₂+C₆, C₆H₄CF₃), 126.0 (C₃+C₅, C₆H₄CF₃, ³J_{CF} = 3.8 Hz), 123.5 (CF₃, ¹J_{CF} = 272 Hz), 86.4 (CH, NC4H), 62.1 (CH₂), 55.9 (CH, SC5H), 14.1 (CH₃). ¹⁹F NMR (CDCl₃, 282.4 MHz): δ = -62.70 (s, CF₃). HRMS (ESI⁺) [*m/z*]: calcd for [C₁₉H₁₅F₃NO₂S]⁺ = [M - H]⁺, 378.0781; found, 378.0797.

trans-(RR/SS) Ethyl 5-(2-Methoxyphenyl)-2-phenyl-4,5-dihydrothiazole-4-carboxylate 6i. Following the general procedure, thiazolone **2i** (150 mg, 0.51 mmol) was reacted with NaOEt (10

mg, 0.09 mmol) for 2 h in refluxing EtOH (10 mL) to give, after chromatographic purification using silica gel as support and *n*-hexane/Et₂O (11:1) as an eluent, *trans*-(RR/SS)-**6i** as a yellow oil. Obtained: 140 mg (80% yield). ¹H NMR (CDCl₃, 300.13 MHz): δ = 7.93 (dd, 2H, H_o, Ph), ³J_{HH} = 8.2 Hz, ⁴J_{HH} = 1.4 Hz), 7.51 (tt, 1H, H_p, Ph), ³J_{HH} = 8.2 Hz, ⁴J_{HH} = 1.4 Hz), 7.44 (t, 2H, H_m, Ph), ³J_{HH} = 8.2 Hz), 7.39 (dd, 1H, H₆, C₆H₄OMe, ³J_{HH} = 7.7 Hz, ⁴J_{HH} = 0.7 Hz), 7.29 (td, 1H, H₅, C₆H₄OMe, ³J_{HH} = 7.7 Hz, ⁴J_{HH} = 0.7 Hz), 6.96 (td, 1H, H₄, C₆H₄OMe, ³J_{HH} = 7.7 Hz, ⁴J_{HH} = 0.7 Hz), 6.92 (d, 1H, H₃, C₆H₄OMe, ⁴J_{HH} = 0.7 Hz), 5.81 (AB spin system, 1H, NCH, ³J_{HH} = 5.1 Hz), 5.45 (AB spin system, 1H, SCH, ³J_{HH} = 5.1 Hz), 4.29 (q, 2H, OCH₂CH₃, ³J_{HH} = 7.1 Hz), 3.87 (s, 3H, OMe), 1.33 (t, 3H, OCH₂CH₃, ³J_{HH} = 7.1 Hz). ¹³C{¹H} NMR (CDCl₃, 75.5 MHz): δ = 170.9 (NCS), 170.4 (COO), 156.5 (C₂-OMe, C₆H₄OMe), 132.9 (C_v, Ph), 131.6 (C_p, Ph), 129.2 (C₄/C₅, C₆H₄OMe), 128.8 (C₁, C₆H₄OMe), 128.7 (C_o, Ph), 128.5 (C_m, Ph), 127.8 (C₆, C₆H₄OMe), 121.0 (C₄/C₅, C₆H₄OMe), 110.7 (C₃, C₆H₄OMe), 84.4 (CH, NCH), 61.7 (OCH₂), 55.5 (CH₃, OMe), 50.4 (CH, SCH), 14.2 (CH₃). HRMS (ESI⁺) [*m/z*]: calcd for [C₁₉H₁₉NNaO₃S]⁺ = [M + Na]⁺, 364.0983; found, 364.0978.

trans-(RR/SS) Ethyl 5-(3,4-Dimethylphenyl)-2-phenyl-4,5-dihydrothiazole-4-carboxylate 6m. Following the general procedure, thiazolone **2m** (150 mg, 0.51 mmol) was reacted with NaOEt (10 mg, 0.09 mmol) for 4 h in refluxing EtOH (10 mL) to give, after chromatographic purification using silica gel as support and *n*-hexane/Et₂O (8:1) as an eluent, *trans*-(RR/SS)-**6m** as a yellow oil. Obtained: 129 mg (75% yield). ¹H NMR (CDCl₃, 300.13 MHz): 7.94 (d, 2H, H_o, Ph), ³J_{HH} = 6.8 Hz), 7.53–7.43 (m, 3H, H_p + 2H_m, Ph), 7.19 (s, 1H, H₂, C₆H₃(Me)₂), 7.16, 7.12 (AB spin system, 2H, H₅ + H₆, ³J_{HH} = 7.5 Hz, C₆H₃(Me)₂), 5.41 (AB spin system, CH, ³J_{HH} = 6.6 Hz), 5.36 (AB spin system, CH, ³J_{HH} = 6.6 Hz), 4.31 (q, 1H, OCH₂CH₃, ³J_{HH} = 7.1 Hz), 4.29 (q, 1H, OCH₂CH₃, ³J_{HH} = 7.1 Hz), 2.27 (s, 6H, 2CH₃), 1.33 (t, 3H, OCH₂CH₃, ³J_{HH} = 7.1 Hz). ¹³C{¹H} NMR (CDCl₃, 75.5 MHz): 170.4 (NCS), 170.4 (COO), 137.8, 137.3, 136.7 (3C_q, C₁, C₃, C₄, C₆H₃(Me)₂), 132.7 (C_v, Ph), 131.8 (C_p, Ph), 130.2 (CH, C₆/C₅, C₆H₃(Me)₂), 128.7 (C_o, Ph), 128.7 (CH, C₂, C₆H₃(Me)₂), 128.6 (C_m, Ph), 124.9 (CH, C₆/C₅, C₆H₃(Me)₂), 86.6 (NCH), 61.9 (OCH₂), 56.5 (SCH), 19.8 (CH₃), 19.5 (CH₃), 14.2 (OCH₂CH₃). HRMS (ESI⁺) [*m/z*]: calcd for [C₂₀H₂₂NO₂S]⁺ = [M + H]⁺, 340.1366; found, 340.1359.

trans-(RR/SS) Ethyl 5-(3,4-Dichlorophenyl)-2-phenyl-4,5-dihydrothiazole-4-carboxylate (6n) and Ethyl 5-(3,4-Dichlorophenyl)-2-phenylthiazole-4-carboxylate (7n). Following the general procedure, thiazolone **2n** (270 mg, 0.81 mmol) was reacted with NaOEt (10 mg, 0.09 mmol) for 2 h in refluxing EtOH (10 mL) to give a waxy orange solid. This solid is composed of dihydrothiazole **6n** and thiazole **7n**. These compounds were separated and purified by column chromatography using silica gel as support. Using a mixture of *n*-hexane/Et₂O (4:1) as an eluent, the thiazole **7n** eluted first. Evaporation of the solvent gave pure **7n** as white crystals. Obtained: 128 mg (42% yield). Further elution with the same mixture of solvents gave *trans*-(RR/SS)-**6n** as a yellow oil. Obtained: 70 mg (24% yield)

Ethyl 5-(3,4-Dichlorophenyl)-2-phenyl-4,5-dihydrothiazole-4-carboxylate (6n). ¹H NMR (CDCl₃, 300.13 MHz): δ = 7.93 (d, 2H, H_o, Ph), ³J_{HH} = 7.0 Hz), 7.55–7.43 (m, 5H, H_p+H_m (Ph) + H₅ + H₆(C₆H₃Cl₂)), 7.28 (s, 1H, H₂, C₆H₃Cl₂), 5.39 (AB spin system, 1H, SCH, ³J_{HH} = 6.3 Hz), 5.31 (AB spin system, 1H, NCH, ³J_{HH} = 6.3 Hz), 4.31 (q, 1H, OCH₂CH₃, ³J_{HH} = 7.1 Hz), 4.29 (q, 1H, OCH₂CH₃, ³J_{HH} = 7.1 Hz), 1.34 (t, 3H, OCH₂CH₃, ³J_{HH} = 7.1 Hz). ¹³C{¹H} NMR (CDCl₃, 75.5 MHz): 173.6 (NCS), 169.9 (CO), 140.5 (C₁, C₆H₃Cl₂), 132.2 (CH, C₃/C₆, C₆H₃Cl₂), 131.0 (CH, C₃/C₆, C₆H₃Cl₂), 129.6 (C_p, Ph), 128.8 (C_o, Ph), 128.7 (C_m, Ph), 126.6 (CH, C₂, C₆H₃Cl₂), 86.1 (NCH), 62.2 (OCH₂), 55.4 (SCH), 14.1 (CH₃). Signals due to C₃ and C₄ (C₆H₃Cl₂) and to the C_{ipso} (Ph) were not observed. HRMS (ESI⁺) [*m/z*]: calcd for [C₁₈H₁₆Cl₂NO₂S]⁺ = [M + H]⁺, 380.0279; found, 380.0289.

Ethyl 5-(3,4-Dichlorophenyl)-2-phenylthiazole-4-carboxylate (7n). ¹H NMR (CDCl₃, 300.13 MHz): δ = 8.01 (m, 2H, H_o, Ph), 7.67 (d, 1H, H₂, C₆H₃Cl₂), ⁴J_{HH} = 2 Hz), 7.54–7.48 (m, 4H, H_p+H_m

(Ph) + H₃(C₆H₃Cl₂), 7.40 (dd, 1H, H₆, C₆H₃Cl₂, ³J_{HH} = 8.3 Hz, ⁴J_{HH} = 2.1 Hz), 4.35 (q, 2H, OCH₂CH₃, ³J_{HH} = 7.1 Hz), 1.31 (t, 3H, OCH₂CH₃, ³J_{HH} = 7.1 Hz). ¹³C{¹H} NMR (CDCl₃, 75.5 MHz): δ = 166.8 (NCS), 161.9 (CO), 142.6, 142.2 (S-C=C-N), 133.5 (C, C₆H₃Cl₂), 132.5, 132.5 (2C, C-Cl, C₆H₃Cl₂), 131.8 (CH, C₂, C₆H₃Cl₂), 130.9 (C_p, Ph), 130.5 (C_v, Ph), 130.1 (CH, C₅, C₆H₃Cl₂), 129.3 (CH, C₆, C₆H₃Cl₂), 129.0 (C_m, Ph), 126.9 (C_o, Ph), 61.5 (CH₂), 14.1 (CH₃). HRMS (ESI⁺) [*m/z*]: calcd for [C₁₈H₁₃Cl₂NNaO₂S]⁺ = [M + Na]⁺, 399.9942; found, 399.9945.

Microwave Synthesis of Methyl 5-(4-Nitrophenyl)-2-phenyl-4,5-thiazole-4-carboxylate 7g. To a suspension of thiazolone **2g** (300 mg, 0.97 mmol) in methanol (5 mL) was added NaOMe (9 mg). The mixture was heated in a microwave oven (150 W, 70 °C) for 1 min. After the reaction time, the solvent was evaporated to dryness, and the solid residue was extracted with CH₂Cl₂ (10 mL). The resulting suspension was filtered through a Celite pad, and the Celite was washed with additional CH₂Cl₂ (20 mL). The clear solution was evaporated to dryness, and the crude was characterized by NMR and was shown to contain thiazole **7g**. Compound **7g** was purified by column chromatography (silica gel; *n*-hexane/Et₂O = 5:1 as an eluent), giving pure **7g** as white crystals. Obtained: 64 mg (20% yield). ¹H NMR (CDCl₃, 300.13 MHz): δ = 8.33 (AB spin system, 2H, H₂+H₅, C₆H₄NO₂), 8.02 (m, 2H, H_o, Ph), 7.74 (AB spin system, 2H, H₂+H₆, C₆H₄NO₂), 7.51 (m, 3H, H_p+H_m, Ph), 3.91 (s, 3H, OMe). ¹³C{¹H} NMR (CDCl₃, 75.5 MHz): 167.6 (NCS), 162.3 (CO), 148.1 (C, S-C =), 143.1 (C₄-N, C₆H₄NO₂), 141.9 (C, N-C =), 137.0 (C₁, C₆H₄NO₂), 132.3 (C_v, Ph), 131.2 (C_p, Ph), 131.0 (C₂/C₆, C₆H₄NO₂), 129.2 (C_m, Ph), 126.7 (C_o, Ph), 123.4 (C₃/C₅, C₆H₄NO₂), 52.6 (OCH₃). HRMS (ESI⁺) [*m/z*]: calcd for [C₁₇H₁₂N₂NaO₄S]⁺ = [M + Na]⁺, 363.0415; found, 363.0410.

Synthesis of Dihydrothiazole Derivatives (cis/trans)-5 through Ring-Opening Reaction without a Base in the Presence of BF₃ (General Procedure). All syntheses of (cis/trans)-methyl 5-aryl-2-phenyl-4,5-dihydrothiazole-4-carboxylates (cis/trans)-**5** were performed using the same experimental method, which is detailed here for the synthesis of **5a**. To a suspension of the thiazolone **2a** (100.7 mg, 0.38 mmol) in methanol (5 mL) was added BF₃·OEt₂ (200 μL, 1.621 mmol). The resulting mixture was heated in an oil bath at a reflux temperature with stirring for 18 h. After the reaction time, the solvent was evaporated to dryness, and the oily residue was dissolved in CH₂Cl₂ (5 mL). This solution was washed with H₂O (3 × 2 mL), dried with anhydrous MgSO₄, and evaporated to dryness, giving **5a** as the mixture of the two diastereoisomers *trans* (RR/SS) and *cis* (RS/SR) in a 1:1 molar ratio. Obtained: 83.04 mg (74% yield)

(cis/trans)-Methyl 2,5-Diphenyl-4,5-dihydrothiazole-4-carboxylate 5a. ¹H NMR (CDCl₃, 300.13 MHz): δ = 7.96 (m, H_o, NCS-Ph), 7.90 (m, H_o, NCS-Ph), 7.52–7.21 (m, H_m+H_p, NCS-Ph, H_o+H_m+H_p, Ph, both isomers), 5.55 (d, NCH, ³J_{HH} = 9.0 Hz, *cis*-isomer), 5.45 (d, SCH, ³J_{HH} = 6.5 Hz, *trans*-isomer), 5.37 (d, NCH, ³J_{HH} = 6.5 Hz, *trans*-isomer), 5.23 (d, SCH, ³J_{HH} = 9.0 Hz, *cis*-isomer), 3.79 (s, OMe, *trans*-isomer), 3.34 (s, OMe, *cis*-isomer). ¹³C{¹H} NMR (CDCl₃, 75.5 MHz): δ = 170.7 (SC = N), 170.7 (COO), 170.5 (SC = N), 169.2 (COO), 140.3, 138.1 (C_v, Ph, both isomers), 132.5 (C_v, NCS-Ph, overlapped), 132.0, 131.9 (2C_p, NCS-Ph, both isomers), 129.0, 128.8, 128.7, 128.6, 128.4, 127.9, 127.5 (C_o, C_m, NCS-Ph; C_o, C_m, Ph; both isomers), 128.4, 128.2 (C_p, Ph both isomers), 86.5 (NCH, *trans*-isomer), 83.9 (NCH, *cis*-isomer), 56.6 (SCH, *trans*-isomer), 55.8 (SCH, *cis*-isomer), 52.9 (OMe, *trans*-isomer), 51.9 (OMe, *cis*-isomer). HRMS (ESI⁺) [*m/z*]: calcd for [C₁₇H₁₆NO₂S]⁺ = [M + H]⁺, 298.0896; found, 298.0893.

(cis/trans)-Methyl 2-Phenyl-5-(*p*-tolyl)-4,5-dihydrothiazole-4-carboxylate 5b. Following the general procedure, thiazolone **2b** (101.4 mg, 0.363 mmol) was reacted with BF₃·OEt₂ (200 μL, 1.621 mmol) for 18 h in refluxing MeOH (5 mL) to give (cis/trans)-**5b** (1:1.1 molar ratio) as a yellow oil. Obtained: 80 mg (71% yield). ¹H NMR (CDCl₃, 300.13 MHz): δ = 7.98 (m, H_o, NCS-Ph), 7.91 (m, H_o, NCS-Ph), 7.55–7.41 (m, H_m, H_p, NCS-Ph, both isomers), 7.30 (d, H_o, C₆H₄Me, ³J_{HH} = 8.1 Hz), 7.16 (d, H_o, H_m, C₆H₄Me, ³J_{HH} = 7.8 Hz), 7.06 (d, H_m, C₆H₄Me, ³J_{HH} = 8.1 Hz), 5.55 (d, NCH, ³J_{HH} = 8.9 Hz, *cis*-isomer), 5.44 (d, SCH, ³J_{HH} = 6.6 Hz, *trans*-isomer), 5.36

(d, NCH, ³J_{HH} = 6.6 Hz, *trans*-isomer), 5.23 (d, SCH, ³J_{HH} = 8.9 Hz, *cis*-isomer), 3.82 (s, OMe, *trans*-isomer), 3.40 (s, OMe, *cis*-isomer), 2.34 (s, Me), 2.30 (s, Me). ¹³C{¹H} NMR (CDCl₃, 75.5 MHz): δ = 170.9 (SC = N), 170.8 (SC = N), 170.6 (COO), 169.5 (COO), 138.3 (C_p, C₆H₄Me), 138.2 (C_p, C₆H₄Me), 137.4 (C_v, C₆H₄Me), 135.2 (C_v, C₆H₄Me), 132.7 (C_v, NCS-Ph, both isomers, overlapped), 132.0, 131.9 (2C_p, NCS-Ph, both isomers), 129.8, 129.2, 128.9, 128.8, 128.7 (2C overlapped), 127.8, 127.5 (C_o, C_m, NCS-Ph + C_o, C_m, C₆H₄Me), 86.6 (NCH, *trans*-isomer), 84.0 (NCH, *cis*-isomer), 56.6 (SCH, *trans*-isomer), 55.8 (SCH, *cis*-isomer), 53.0 (OMe, *trans*-isomer), 52.0 (OMe, *cis*-isomer), 21.3 (Me), 21.2 (Me). HRMS (ESI⁺) [*m/z*]: calcd for [C₁₈H₁₇NO₂SN₂Na]⁺ = [M + Na]⁺, 334.0872; found, 334.0877.

(cis/trans)-Methyl 2-Phenyl-5-(4-methoxyphenyl)-4,5-dihydrothiazole-4-carboxylate 5c. Following the general procedure, thiazolone **2c** (100.3 mg, 0.34 mmol) was reacted with BF₃·OEt₂ (200 μL, 1.621 mmol) for 18 h in refluxing MeOH (5 mL) to give (cis/trans)-**5c** (1:1.1 molar ratio) as a yellow oil. In this case, further chromatographic purification was necessary to separate **5c** from starting thiazolone **2c**. The chromatographic purification was started using silica as support and *n*-hexane/Et₂O (9:1) as an eluent. Using these conditions, only the thiazolone **2c** was eluted. Then the solvent was changed, and 2-propanol was employed. Using these conditions, the dihydrothiazole **5c** was obtained as a yellow oil after solvent evaporation. Obtained: 42.7 mg (38% yield). ¹H NMR (CDCl₃, 300.13 MHz): δ = 7.96 (m, H_o, NCS-Ph), 7.90 (m, H_o, NCS-Ph), 7.54–7.41 (m, H_m, H_p, NCS-Ph, both isomers), 7.32 (d, H_o, C₆H₄OMe, ³J_{HH} = 8.1 Hz), 7.19 (d, H_o, C₆H₄OMe, ³J_{HH} = 8.1 Hz), 6.87–6.78 (d, H_m, C₆H₄OMe, ³J_{HH} = 8.0 Hz), 5.53 (d, NCH, ³J_{HH} = 8.9 Hz, *cis*-isomer), 5.43 (d, SCH, ³J_{HH} = 6.5 Hz, *trans*-isomer), 5.34 (d, NCH, ³J_{HH} = 6.6 Hz, *trans*-isomer), 5.23 (d, SCH, ³J_{HH} = 8.9 Hz, *cis*-isomer), 3.81 (s, OMe, *trans*-isomer), 3.79, 3.76 (2s, OMe, both isomers), 3.41 (s, OMe, *cis*-isomer). ¹³C{¹H} NMR (CDCl₃, 75.5 MHz): δ = 171.0 (SC = N), 170.9 (SC = N), 170.8 (COO), 169.4 (COO), 159.5 (C_p, C₆H₄OMe), 159.5 (C_p, C₆H₄OMe), 132.6 (C_v, NCS-Ph, both isomers), 132.2 (C_v, C₆H₄OMe), 132.0 (C_p, NCS-Ph), 131.9 (C_p, NCS-Ph), 130.0 (C_v, C₆H₄OMe), 129.1 (C_o, C₆H₄OMe), 128.8 (C_o, C₆H₄OMe), 128.7, 128.6 (C_o, C_m, NCS-Ph, both isomers), 114.4 (C_m, C₆H₄OMe), 113.7 (C_m, C₆H₄OMe), 86.3 (NCH, *trans*-isomer), 83.8 (NCH, *cis*-isomer), 56.2 (SCH, *trans*-isomer), 55.4 (SCH, *cis*-isomer), 55.3 (OMe), 55.2 (OMe), 52.9 (COOMe). HRMS (ESI⁺) [*m/z*]: calcd for [C₁₈H₁₇NO₂SN₂Na]⁺ = [M + Na]⁺, 350.0821; found, 350.0823.

(cis/trans)-Methyl 5-(4-Fluorophenyl)-2-phenyl-4,5-dihydrothiazole-4-carboxylate 5d. Following the general procedure, thiazolone **2d** (102.0 mg, 0.360 mmol) was reacted with BF₃·OEt₂ (200 μL, 1.621 mmol) for 18 h in refluxing MeOH (5 mL) to give (cis/trans)-**5d** (1:1.1 molar ratio) as a yellow oil. In this case, further chromatographic purification was necessary to separate **5d** from starting thiazolone **2d**. The chromatographic purification was started using silica as support and *n*-hexane/Et₂O (9:1) as an eluent. Using these conditions, only the thiazolone **2d** was eluted. Then the solvent was changed, and 2-propanol was employed. Using these conditions, the dihydrothiazole **5d** was obtained as a yellow oil after solvent evaporation. Obtained: 81 mg (71% yield). ¹H NMR (CDCl₃, 300.13 MHz): δ = 7.99 (m, H_o, NCS-Ph), 7.93 (m, H_o, NCS-Ph), 7.55–7.43 (m, H_p+H_m, NCS-Ph, both isomers), 7.40 (m, H_o, C₆H₄F), 7.28 (m, H_o, C₆H₄F), 7.06 (tt, H_m, C₆H₄F, ³J_{HF} = 8.6 Hz, ⁴J_{HH} = 2.1 Hz), 6.97 (tt, H_m, C₆H₄F, ³J_{HF} = 8.7 Hz, ⁴J_{HH} = 2.0 Hz), 5.57 (d, NCH, ³J_{HH} = 8.9 Hz, *cis*-isomer), 5.47 (d, SCH, ³J_{HH} = 6.5 Hz, *trans*-isomer), 5.35 (d, NCH, ³J_{HH} = 6.5 Hz, *trans*-isomer), 5.26 (d, SCH, ³J_{HH} = 8.9 Hz, *cis*-isomer), 3.85 (s, OMe, *trans*-isomer), 3.43 (s, OMe, *cis*-isomer). ¹³C{¹H} NMR (CDCl₃, 75.5 MHz): δ = 170.7 (COO), 170.5 (SC = N), 170.4 (SC = N), 169.3 (COO), 162.6 (d, C_p-F, C₆H₄F, ¹J_{CF} = 247.4 Hz), 162.6 (d, C_p-F, C₆H₄F, ¹J_{CF} = 247.7 Hz), 136.2 (d, C_v, C₆H₄F, ⁴J_{CF} = 3.3 Hz), 134.1 (d, C_v, C₆H₄F, ⁴J_{CF} = 3.5 Hz), 132.6 (2C_v, NCS-Ph, both isomers overlapped), 132.1, 132.0 (2C_p, NCS-Ph, both isomers), 129.8 (d, C_o, C₆H₄F, ³J_{CF} = 8.3 Hz), 129.3 (d, C_o, C₆H₄F, ³J_{CF} = 8.3 Hz), 128.9, 128.8, 128.7, 128.7 (C_o, C_m, NCS-Ph, both isomers), 116.0 (d, C_m, C₆H₄F, ²J_{CF} = 21.7 Hz), 115.4 (d, C_m,

C_6H_4F , $^2J_{CF} = 21.7$ Hz), 86.8 (NCH, *trans*-isomer), 84.1 (NCH, *cis*-isomer), 56.0 (SCH, *trans*-isomer), 55.2 (SCH, *cis*-isomer), 53.0 (OMe), 52.0 (OMe). ^{19}F NMR ($CDCl_3$, 282.40 MHz): $\delta = -113.67$ (tt, $^3J_{FH} = 8.6$ Hz, $^4J_{FH} = 3.3$ Hz), -113.23 (tt, $^3J_{FH} = 8.5$ Hz, $^4J_{FH} = 3.3$ Hz). HRMS (ESI⁺) [m/z]: calcd for $[C_{17}H_{13}FNO_2S]^+ = [M + H]^+$, 316.0802; found, 316.0796.

(*cis/trans*)-Methyl 5-(4-Chlorophenyl)-2-phenyl-4,5-dihydrothiazole-4-carboxylate **5e**. Following the general procedure, thiazolone **2e** (300.6 mg, 1.00 mmol) was reacted with $BF_3 \cdot OEt_2$ (600 μ L, 4.863 mmol) for 18 h in refluxing MeOH (15 mL) to give (*cis/trans*)-**5e** (1:1.7 molar ratio) as a yellow oil. In this case, chromatographic purification was carried out to separate (*cis/trans*)-**5e** from thiazolone **2e** and to further separate *cis*-**5e** from *trans*-**5e**. The chromatographic purification was started using silica as support and *n*-hexane/ Et_2O (9:1) as an eluent. Using these conditions, only the thiazolone **2e** was eluted. Then the solvent was changed, and a mixture, *n*-hexane/ethyl acetate (8:2), was used as an eluent. Compound *trans*-**5e** eluted first and was obtained as a yellow oil after solvent evaporation (obtained: 90 mg, 27% yield). Compound *cis*-**5e** eluted in a second fraction and was obtained as a yellow oil after solvent evaporation (obtained: 54 mg, 16% yield). 1H NMR ($CDCl_3$, 300.13 MHz): $\delta = 7.95$ (m, H_o , NCS-Ph), 7.89 (m, H_o , NCS-Ph), 7.55–7.40 (m, H_m , H_p , NCS-Ph both isomers), 7.33 (d, H_o , H_m , C_6H_4Cl), 7.22 (d, H_o , H_m , C_6H_4Cl), 5.56 (d, NCH, $^3J_{HH} = 8.9$ Hz, *cis*-isomer), 5.42 (d, SCH, $^3J_{HH} = 6.4$ Hz, *trans*-isomer), 5.32 (d, NCH, $^3J_{HH} = 6.4$ Hz, *trans*-isomer), 5.21 (d, SCH, $^3J_{HH} = 8.9$ Hz, *cis*-isomer), 3.82 (s, OMe, *trans*-isomer), 3.42 (s, OMe, *cis*-isomer). $^{13}C\{^1H\}$ NMR ($CDCl_3$, 75.5 MHz): $\delta = 170.7$ (SC = N), 170.7 (SC = N), 170.6 (COO), 169.3 (COO), 138.2 (C_i , C_6H_4Cl), 136.9 (C_i , C_6H_4Cl), 134.4 (C_p , C_6H_4Cl), 134.2 (C_p , C_6H_4Cl), 132.5 (C_i , NCS-Ph, both isomers), 132.2 (C_p , NCS-Ph), 132.1 (C_p , NCS-Ph), 129.4, 128.9 (C_o , C_m , C_6H_4Cl), 129.3, 129.0 (C_o , C_m , C_6H_4Cl), 128.8, 128.8 (C_o , C_m , NCS-Ph), 128.8, 128.8 (C_o , C_m , NCS-Ph), 86.6 (NCH, *trans*-isomer), 83.9 (NCH, *cis*-isomer), 56.0 (SCH, *trans*-isomer), 55.2 (SCH, *cis*-isomer), 53.1 (OMe, *trans*-isomer), 52.2 (OMe, *cis*-isomer). HRMS (ESI⁺) [m/z]: calcd for $[C_{17}H_{14}ClNO_2SNa]^+ = [M + Na]^+$, 354.0326; found, 354.0325.

(*cis/trans*)-Methyl 5-(4-Trifluoromethylphenyl)-2-phenyl-4,5-dihydrothiazole-4-carboxylate **5h**. Following the general procedure, thiazolone **2h** (103.60 mg, 0.311 mmol) was reacted with $BF_3 \cdot OEt_2$ (200 μ L, 1.621 mmol) for 18 h in refluxing MeOH (5 mL) to give (*cis/trans*)-**5h** (1:2.1 molar ratio) as a yellow oil. In this case, further chromatographic purification was necessary to separate **5h** from starting thiazolone **2h**. The chromatographic purification was started using silica as support and *n*-hexane/ Et_2O (9:1) as an eluent. Using these conditions, only the thiazolone **2h** was eluted. Then the solvent was changed, and 2-propanol was employed. Using these conditions, the dihydrothiazole **5h** was obtained as a yellow oil after solvent evaporation. Obtained: 38 mg (34% yield). 1H NMR ($CDCl_3$, 300.13 MHz): $\delta = 7.95$ (m, H_o , NCS-Ph), 7.91 (m, H_o , NCS-Ph), 7.61 (d, H_m , $C_6H_4-CF_3$, $^3J_{HH} = 8.1$ Hz, both isomers), 7.54–7.50 (m, H_p , NCS-Ph both isomers, H_o , $C_6H_4-CF_3$), 7.40–7.42 (m, H_m , NCS-Ph, both isomers), 7.39 (d, 2H, H_o , $C_6H_4-CF_3$, $^3J_{HH} = 8.2$ Hz), 5.60 (d, NCH, $^3J_{HH} = 8.9$ Hz, *cis*-isomer), 5.49 (d, SCH, $^3J_{HH} = 6.4$ Hz, *trans*-isomer), 5.35 (d, NCH, $^3J_{HH} = 6.4$ Hz, *trans*-isomer), 5.28 (d, SCH, $^3J_{HH} = 8.9$ Hz, *cis*-isomer), 3.83 (s, OMe, *trans*-isomer), 3.39 (s, OMe, *cis*-isomer). $^{13}C\{^1H\}$ NMR ($CDCl_3$, 75.5 MHz): $\delta = 173.4$ (SC = N), 172.4 (SC = N), 170.1 (COO), 168.5 (COO), 144.0 (C_i , $C_6H_4-CF_3$), 141.5 (C_i , $C_6H_4-CF_3$), 133.2 (C_p , NCS-Ph), 132.9 (C_p , NCS-Ph), 131.5 (C_i , NCS-Ph), 131.3 (C_i , NCS-Ph), 130.9 (q, C_p-CF_3 , $^2J_{CF} = 32.9$ Hz), 130.8 (q, C_p-CF_3 , $^2J_{CF} = 32.9$ Hz), 129.1, 129.1 (C_o , C_m , NCS-Ph), 129.0, 129.0 (C_o , C_m , NCS-Ph), 128.6 (C_o , $C_6H_4-CF_3$), 128.1 (C_o , $C_6H_4-CF_3$), 126.3 (q, C_m , $C_6H_4-CF_3$, $^3J_{CF} = 3.7$ Hz), 125.7 (q, C_m , $C_6H_4-CF_3$, $^3J_{CF} = 3.7$ Hz), 122.2 (q, CF_3 , $^1J_{CF} = 272$ Hz), 122.1 (q, CF_3 , $^1J_{CF} = 272$ Hz), 85.1 (NCH, *trans*-isomer), 82.2 (NCH, *cis*-isomer), 55.8 (SCH, *trans*-isomer), 55.0 (SCH, *cis*-isomer), 53.4 (OMe, *trans*-isomer), 52.3 (OMe, *cis*-isomer). ^{19}F NMR ($CDCl_3$, 282.40 MHz): $\delta = -62.76$ (s), -62.70 (s). HRMS (ESI⁺) [m/z]: calcd for $[C_{18}H_{14}F_3NO_2SNa]^+ = [M + Na]^+$, 388.0590; found, 388.0584.

(*cis/trans*)-Methyl 5-(2-Bromophenyl)-2-phenyl-4,5-dihydrothiazole-4-carboxylate **5k**. Following the general procedure, thiazolone **2k** (100.4 mg, 0.293 mmol) was reacted with $BF_3 \cdot OEt_2$ (200 μ L, 1.621 mmol) for 18 h in refluxing MeOH (5 mL) to give (*cis/trans*)-**5k** (1:0.8 molar ratio) as a yellow oil. In this case, further chromatographic purification was necessary to separate **5k** from starting thiazolone **2k**. The chromatographic purification was started using silica as support and *n*-hexane/ Et_2O (9:1) as an eluent. Using these conditions, only the thiazolone **2k** was eluted. Then the solvent was changed, and 2-propanol was employed. Using these conditions, the dihydrothiazole **5k** was obtained as a yellow oil after solvent evaporation. Obtained: 30 mg (27% yield). 1H NMR ($CDCl_3$, 300.13 MHz): $\delta = 7.93$ (m, H_o , NCS-Ph), 7.90 (m, H_o , NCS-Ph), 7.59 (dd, H_s , C_6H_4Br , $^3J_{HH} = 8.0$ Hz, $^4J_{HH} = 1.2$ Hz), 7.55–7.52 (m, H_p , NCS-Ph, both isomers, H_s , C_6H_4Br), 7.49–7.42 (m, H_m , NCS-Ph, H_o , C_6H_4Br ; both isomers), 7.30 (td, H_s , C_6H_4Br , $^3J_{HH} = 7.5$ Hz, $^4J_{HH} = 1.2$ Hz), 7.22 (td, H_s , C_6H_4Br , $^3J_{HH} = 7.4$ Hz, $^4J_{HH} = 1.2$ Hz), 7.15 (td, H_o , C_6H_4Br , $^3J_{HH} = 8.0$ Hz, $^4J_{HH} = 1.7$ Hz), 7.10 (td, H_o , C_6H_4Br , $^3J_{HH} = 7.4$ Hz, $^4J_{HH} = 1.7$ Hz), 5.91 (d, SCH, $^3J_{HH} = 9.1$ Hz, *cis*-isomer), 5.89 (d, SCH, $^3J_{HH} = 4.5$ Hz, *trans*-isomer), 5.66 (d, NCH, $^3J_{HH} = 9.1$ Hz, *cis*-isomer), 5.47 (d, NCH, $^3J_{HH} = 4.5$ Hz, *trans*-isomer), 3.83 (s, OMe, *trans*-isomer), 3.40 (s, OMe, *cis*-isomer). $^{13}C\{^1H\}$ NMR ($CDCl_3$, 75.5 MHz): $\delta = 170.9$ (SC = N), 170.8 (SC = N), 170.4 (COO), 169.2 (COO), 140.2 (C_i , C_6H_4Br), 137.9 (C_i , C_6H_4Br), 133.2 (C_3 , C_6H_4Br), 132.8 (C_3 , C_6H_4Br), 132.7 (C_i , NCS-Ph), 132.6 (C_i , NCS-Ph), 132.1 (C_p , NCS-Ph), 132.1 (C_p , NCS-Ph), 129.8 (C_4 , C_6H_4Br), 129.7 (C_4 , C_6H_4Br), 129.2, 128.9 (C_o , C_m , NCS-Ph, both isomers), 128.8 (C_o , C_6H_4Br), 128.8 (C_o , C_6H_4Br), 128.5 (C_5 , C_6H_4Br), 128.1 (C_5 , C_6H_4Br), 123.8 (C_2 -Br, C_6H_4Br), 123.7 (C_2 -Br, C_6H_4Br), 85.1 (NCH, *trans*-isomer), 82.6 (NCH, *cis*-isomer), 55.3 (SCH, *trans*-isomer), 54.5 (SCH, *cis*-isomer), 53.1 (OMe, *trans*-isomer), 52.0 (OMe, *cis*-isomer). HRMS (ESI⁺) [m/z]: calcd for $[C_{17}H_{14}BrNO_2SNa]^+ = [M + Na]^+$, 397.9821; found, 397.9808.

(*cis/trans*)-Methyl 5-(3,4-Dimethylphenyl)-2-phenyl-4,5-dihydrothiazole-4-carboxylate **5m**. Following the general procedure, thiazolone **2m** (101.73 mg, 0.347 mmol) was reacted with $BF_3 \cdot OEt_2$ (200 μ L, 1.621 mmol) for 18 h in refluxing MeOH (5 mL) to give (*cis/trans*)-**5m** (1:0.8 molar ratio) as a yellow oil. Obtained: 95 mg (84% yield). 1H NMR ($CDCl_3$, 300.13 MHz): $\delta = 7.98$ (m, 2H, NCS-Ph), 7.92 (m, H_o , NCS-Ph), 7.55–7.41 (m, H_m , H_p , NCS-Ph, both isomers), 7.18 (s, H_2 , $C_6H_3(Me)_2$), 7.14–7.12 (m, H_5 , H_6 , $C_6H_3(Me)_2$), 7.03 (s, H_2 , $C_6H_3(Me)_2$), 7.02 (m, H_5 , H_6 , $C_6H_3(Me)_2$), 5.55 (d, NCH, $^3J_{HH} = 9.0$ Hz, *cis*-isomer), 5.43 (d, SCH, $^3J_{HH} = 6.7$ Hz, *trans*-isomer), 5.38 (d, NCH, $^3J_{HH} = 6.7$ Hz, *trans*-isomer), 5.22 (d, SCH, $^3J_{HH} = 9.0$ Hz, *cis*-isomer), 3.82 (s, OMe, *trans*-isomer), 3.42 (s, OMe, *cis*-isomer), 2.25 (s, Me, *trans*-isomer), 2.20 (s, Me, *cis*-isomer). $^{13}C\{^1H\}$ NMR ($CDCl_3$, 75.5 MHz): $\delta = 170.9$ (COO + SC = N, overlapped), 170.6 (SC = N), 169.4 (COO), 137.7 (C_i , $C_6H_3(Me)_2$), 137.4, 136.9, 136.8, 136.7 (C_q , C_3 , C_4 , $C_6H_3(Me)_2$ both isomers), 135.5 (C_i , $C_6H_3(Me)_2$), 132.7 (C_i , NCS-Ph), 132.7 (C_i , NCS-Ph), 131.9 (C_p , NCS-Ph), 131.9 (C_p , NCS-Ph), 130.3, 129.7, 125.3, 124.3 (C_5 , C_6 , $C_6H_3(Me)_2$ both isomers), 129.0, 128.9, 128.6 (C_o , C_m , NCS-Ph, both isomers), 128.7 (C_2 , $C_6H_3(Me)_2$), 128.7 (C_2 , $C_6H_3(Me)_2$), 86.5 (NCH, *trans*-isomer), 83.8 (NCH, *cis*-isomer), 56.5 (SCH, *trans*-isomer), 55.7 (SCH, *cis*-isomer), 52.9 (OMe, *trans*-isomer), 51.9 (OMe, *cis*-isomer), 19.9, 19.8, 19.5, 19.5 (Me). HRMS (ESI⁺) [m/z]: calcd for $[C_{19}H_{19}NO_2SNa]^+ = [M + Na]^+$, 348.1029; found, 348.1032.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acs.joc.1c01458>.

Copies of 1H and ^{13}C NMR spectra for all new compounds, copies of the absorption (UV–vis) spectra of thiazolones **2** and selected cyclobutanes **3**, NMR spectra, and UV–vis spectra of **2b** in the presence of BF_3 (PDF)

Accession Codes

CCDC 1912941–1912942, 1958992–1958993, and 1999650 contain the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif, or by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033.

AUTHOR INFORMATION

Corresponding Author

Esteban P. Urriolabeitia – Instituto de Síntesis Química y Catálisis Homogénea, ISQCH (CSIC-Universidad de Zaragoza), 50009 Zaragoza, Spain; orcid.org/0000-0001-9779-5820; Email: esteban@unizar.es

Authors

Sonia Sierra – Instituto de Síntesis Química y Catálisis Homogénea, ISQCH (CSIC-Universidad de Zaragoza), 50009 Zaragoza, Spain

David Dalmau – Instituto de Síntesis Química y Catálisis Homogénea, ISQCH (CSIC-Universidad de Zaragoza), 50009 Zaragoza, Spain

Sheila Higuera – Instituto de Síntesis Química y Catálisis Homogénea, ISQCH (CSIC-Universidad de Zaragoza), 50009 Zaragoza, Spain

Darío Cortés – Instituto de Síntesis Química y Catálisis Homogénea, ISQCH (CSIC-Universidad de Zaragoza), 50009 Zaragoza, Spain

Olga Crespo – Instituto de Síntesis Química y Catálisis Homogénea, ISQCH (CSIC-Universidad de Zaragoza), 50009 Zaragoza, Spain; orcid.org/0000-0001-9522-5840

Ana I. Jimenez – Instituto de Síntesis Química y Catálisis Homogénea, ISQCH (CSIC-Universidad de Zaragoza), 50009 Zaragoza, Spain

Alexandra Pop – Supramolecular Organic and Organometallic Chemistry Centre, Department of Chemistry, Faculty of Chemistry and Chemical Engineering, Babeş-Bolyai University, 400028 Cluj–Napoca, Romania

Cristian Silvestru – Supramolecular Organic and Organometallic Chemistry Centre, Department of Chemistry, Faculty of Chemistry and Chemical Engineering, Babeş-Bolyai University, 400028 Cluj–Napoca, Romania; orcid.org/0000-0001-5124-9525

Complete contact information is available at: <https://pubs.acs.org/10.1021/acs.joc.1c01458>

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We thank the Gobierno de Aragón-FSE (Spain, research groups Aminoácidos y Péptidos E19_20R and Química de Oro y Plata E07_20R) and the Spanish Government (Agencia Estatal de Investigación: projects nos. PID2019-106394GB-I00 and PID2019-104379RB-C21) for funding. A.P. is grateful for financial support of the Romanian Ministry of Education and Research through the grant PN-III-P1-1.1-MC-2018-2580. S.S. thanks gobierno de Aragón-FSE for a Ph.D. fellowship.

REFERENCES

- (1) Poplata, S.; Tröster, A.; Zou, Y.-Q.; Bach, T. Recent Advances in the Synthesis of Cyclobutanes by Olefin [2 + 2] Photocycloaddition Reactions. *Chem. Rev.* **2016**, *116*, 9748–9815.
- (2) Dembitsky, V. M. Naturally Occurring Bioactive Cyclobutane-Containing (CBC) Alkaloids in Fungi, Fungal Endophytes, and Plants. *Phytomedicine* **2014**, *21*, 1559–1581.
- (3) Marson, C. M. New and Unusual Scaffolds in Medicinal Chemistry. *Chem. Soc. Rev.* **2011**, *40*, 5514.
- (4) Kim, J.; Bogdan, D. M.; Elmes, M. W.; Awwa, M.; Yan, S.; Che, J.; Lee, G.; Deutsch, D. G.; Rizzo, R. C.; Kaczocha, M.; Ojima, I. Incarvilleine Produces Antinociceptive and Motor Suppressive Effects via Adenosine Receptor Activation. *PLoS One* **2019**, *14*, No. e0218619.
- (5) Tsai, I.-L.; Lee, F.-P.; Wu, C.-C.; Duh, C.-Y.; Ishikawa, T.; Chen, J.-J.; Chen, Y.-C.; Seki, H.; Chen, I.-S. New Cytotoxic Cyclobutanoid Amides, a New Furanoid Lignan and Anti-Platelet Aggregation Constituents from *Piper arborescens*. *Planta Med.* **2005**, *71*, 535–542.
- (6) Fan, Y.-Y.; Zhang, H.; Zhou, Y.; Liu, H.-B.; Tang, W.; Zhou, B.; Zuo, J.-P.; Yue, J.-M. Phainanoids A-F, A New Class of Potent Immunosuppressive Triterpenoids with an Unprecedented Carbon Skeleton from *Phyllanthus Hainanensis*. *J. Am. Chem. Soc.* **2015**, *137*, 138–141.
- (7) Li, J.; Gao, K.; Bian, M.; Ding, H. Recent advances in the total synthesis of cyclobutane-containing natural products. *Org. Chem. Front.* **2020**, *7*, 136–154.
- (8) Reissig, H. U.; Zimmer, R. Thrilling Strain! Donor-Acceptor-Substituted Cyclobutanes for the Synthesis of (Hetero)Cyclic Compounds. *Angew. Chem., Int. Ed.* **2015**, *54*, 5009–5011.
- (9) Hu, J.-L.; Wang, L. J.; Xu, H.; Xie, Z. W.; Tang, Y. Highly Diastereoselective and Enantioselective Formal [4 + 3] Cycloaddition of Donor-Acceptor Cyclobutanes with Nitrones. *Org. Lett.* **2015**, *17*, 2680–2683.
- (10) Perrotta, D.; Racine, S.; Vuilleumier, J.; de Nanteuil, F.; Waser, J. [4 + 2]-Annulations of Aminocyclobutanes. *Org. Lett.* **2015**, *17*, 1030–1033.
- (11) Stevens, A. C.; Palmer, C.; Pagenkopf, B. L. The Formal [4 + 3] Cycloaddition between Donor-Acceptor Cyclobutanes and Nitrones. *Org. Lett.* **2011**, *13*, 1528–1531.
- (12) Hu, J.-L.; Feng, L.-W.; Wang, L.; Xie, Z.; Tang, Y.; Li, X. Enantioselective Construction of Cyclobutanes: A New and Concise Approach to the Total Synthesis of (+)-Piperarborene B. *J. Am. Chem. Soc.* **2016**, *138*, 13151–13154.
- (13) Gutekunst, W. R.; Baran, P. S. Applications of C-H Functionalization Logic to Cyclobutane Synthesis. *J. Org. Chem.* **2014**, *79*, 2430–2452.
- (14) Parella, R.; Gopalakrishnan, B.; Babu, S. A. Direct Bis-Arylation of Cyclobutanecarboxamide via Double C-H Activation: An Auxiliary-Aided Diastereoselective Pd-Catalyzed Access to Trisubstituted Cyclobutane Scaffolds Having Three Contiguous Stereocenters and an All-cis Stereochemistry. *J. Org. Chem.* **2013**, *78*, 11911–11934.
- (15) Panish, R. A.; Chintala, S. R.; Fox, J. M. A Mixed-Ligand Chiral Rhodium(II) Catalyst Enables the Enantioselective Total Synthesis of Piperarborene B. *Angew. Chem., Int. Ed.* **2016**, *55*, 4983–4987.
- (16) Cohen, M. D.; Schmidt, G. M. J.; Sonntag, F. I. 384. Topochemistry. Part II. The photochemistry of trans-cinnamic acids. *J. Chem. Soc.* **1964**, 2000–2013.
- (17) Schmidt, G. M. J. Photodimerization in the solid state. *Pure Appl. Chem.* **1971**, *27*, 647–678.
- (18) Ramamurthy, V.; Venkatesan, K. Photochemical reactions of organic crystals. *Chem. Rev.* **1987**, *87*, 433–481.
- (19) Alonso, R.; Bach, T. A Chiral Thioxanthone as an Organocatalyst for Enantioselective [2 + 2] Photocycloaddition Reactions Induced by Visible Light. *Angew. Chem., Int. Ed.* **2014**, *53*, 4368–4371.
- (20) Huo, H.; Shen, X.; Wang, C.; Zhang, L.; Röse, P.; Chen, L.-A.; Harms, K.; Marsch, M.; Hilt, G.; Meggers, E. Asymmetric photoredox transition-metal catalysis activated by visible light. *Nature* **2014**, *515*, 100–103.

- (21) Du, J.; Skubi, K. L.; Schultz, D. M.; Yoon, T. P. A Dual Catalysis Approach to Enantioselective [2 + 2] Photocycloadditions Using Visible Light. *Science* **2014**, *344*, 392–396.
- (22) Brimiouille, R.; Lenhart, D.; Maturi, M. M.; Bach, T. Enantioselective Catalysis of Photochemical Reactions. *Angew. Chem., Int. Ed.* **2015**, *54*, 3872–3890.
- (23) Brimiouille, R.; Bauer, A.; Bach, T. Enantioselective Lewis Acid Catalysis in Intramolecular [2 + 2] Photocycloaddition Reactions: A Mechanistic Comparison between Representative Coumarin and Enone Substrates. *J. Am. Chem. Soc.* **2015**, *137*, 5170–5176.
- (24) Coote, S. C.; Pothig, A.; Bach, T. Enantioselective Template-Directed [2 + 2] Photocycloadditions of Isoquinolones: Scope, Mechanism and Synthetic Applications. *Chem. - Eur. J.* **2015**, *21*, 6906–6912.
- (25) Zhao, G.; Yang, C.; Sun, H.; Lin, R.; Xia, W. (+)-Camphor Derivative Induced Asymmetric [2 + 2] Photoaddition Reaction. *Org. Lett.* **2012**, *14*, 776–779.
- (26) Tröster, A.; Alonso, R.; Bauer, A.; Bach, T. Enantioselective Intermolecular [2 + 2] Photocycloaddition. Reactions of 2(1H)-Quinolones Induced by Visible Light Irradiation. *J. Am. Chem. Soc.* **2016**, *138*, 7808–7811.
- (27) Poplata, S.; Bach, T. Enantioselective Intermolecular [2 + 2] Photocycloaddition Reaction of Cyclic Enones and its Application in a Synthesis of (-)-Grandisol. *J. Am. Chem. Soc.* **2018**, *140*, 3228–3231.
- (28) Leverenz, M.; Merten, C.; Dreuw, A.; Bach, T. Lewis Acid Catalyzed Enantioselective Photochemical Rearrangements on the Singlet Potential Energy Surface. *J. Am. Chem. Soc.* **2019**, *141*, 20053–20057.
- (29) Nikitas, N. F.; Gkizis, P. L.; Kokotos, C. G. Thioxanthone: a powerful photocatalyst for organic reactions. *Org. Biomol. Chem.* **2021**, *19*, 5237–5253.
- (30) Sicignano, M.; Rodríguez, R. I.; Alemán, J. Recent Visible Light and Metal Free Strategies in [2 + 2] and [4 + 2] Photocycloadditions. *Eur. J. Org. Chem.* **2021**, *2021*, 3303–3321.
- (31) Marra, I. F. S.; de Almeida, A. M.; Silva, L. P.; de Castro, P. P.; Correa, C. C.; Amarante, G. W. Stereoselective Intermolecular [2 + 2] Cycloadditions of Erlenmeyer-Plöchl Azlactones Using Visible Light Photoredox Catalysis. *J. Org. Chem.* **2018**, *83*, 15144–15154.
- (32) Berger, W. T.; Ralph, B. P.; Kaczocha, M.; Sun, J.; Balius, T. E.; Rizzo, R. C.; Haj-Dahmane, S.; Ojima, I.; Deutsch, D. G. Targeting Fatty Acid Binding Protein (FABP) Anandamide Transporters - A Novel Strategy for Development of Anti-Inflammatory and Anti-Nociceptive Drugs. *PLoS One* **2012**, *7*, No. e50968.
- (33) Yan, S.; Elmes, M. W.; Tong, S.; Hu, K.; Awwa, M.; Teng, G. Y. H.; Jing, Y.; Freitag, M.; Gan, Q.; Clement, T.; Wei, L.; Sweeney, J. M.; Joseph, O. M.; Che, J.; Carbonetti, G. S.; Wang, L.; Bogdan, D. M.; Falcone, J.; Smietalo, N.; Zhou, Y.; Ralph, B.; Hsu, H.-C.; Li, H.; Rizzo, R. C.; Deutsch, D. G.; Kaczocha, M.; Ojima, I. SAR studies on truxillic acid mono esters as a new class of antinociceptive agents targeting fatty acid binding proteins. *Eur. J. Med. Chem.* **2018**, *154*, 233–252.
- (34) Kaczocha, M.; Rebecchi, M. J.; Ralph, B. P.; Teng, Y.-H. G.; Berger, W. T.; Galbavy, W.; Elmes, M. W.; Glaser, S. T.; Wang, L.; Rizzo, R. C.; Deutsch, D. G.; Ojima, I. Inhibition of Fatty Acid Binding Proteins Elevates Brain Anandamide Levels and Produces Analgesia. *PLoS One* **2014**, *9*, No. e94200.
- (35) Ojima, I.; Deutsch, D.; Kaczocha, M.; Berger, W. T.; Rizzo, R.; Balius, T. E. Alpha and gamma-truxillic and derivatives and pharmaceutical compositions thereof, US Patent US 10213406 B2, US Patent Application Publication US2019/0201365 A1.
- (36) Kim, J.; Bogdan, D. M.; Elmes, M. W.; Awwa, M.; Yan, S.; Che, J.; Lee, G.; Deutsch, D. G.; Rizzo, R. C.; Kaczocha, M.; Ojima, I. Incarvilleatine produces antinociceptive and motor suppressive effects via adenosine receptor activation. *PLoS One* **2019**, *14*, No. e0218619.
- (37) Priebe, A.; Hunke, M.; Tonello, R.; Sonawane, Y.; Berta, T.; Natarajan, A.; Bhuvanesh, N.; Pattabiraman, M.; Chandra, S. Ferulic acid dimer as a non-opioid therapeutic for acute pain. *J. Pain Res.* **2018**, *11*, 1075–1085.
- (38) Liu, Q.; Li, N.; Yuan, Y.; Lu, H.; Wu, X.; Zhou, C.; He, M.; Su, H.; Zhang, M.; Wang, J.; Wang, B.; Wang, Y.; Ma, D.; Ye, Y.; Weiss, H. C.; Gesing, E. R. F.; Liao, J.; Wang, M. W. Cyclobutane Derivatives As Novel Nonpeptidic Small Molecule Agonists of Glucagon-Like Peptide-1 Receptor. *J. Med. Chem.* **2012**, *55*, 250–267.
- (39) Chen, D.; Liao, J.; Li, N.; Zhou, C.; Liu, Q.; Wang, G.; Zhang, R.; Zhang, S.; Lin, L.; Chen, K.; Xie, X.; Nan, F.; Young, A. A.; Wang, M.-W. A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice. *Proc. Natl. Acad. Sci. U. S. A.* **2007**, *104*, 943–948.
- (40) de Graaf, C.; Donnelly, D.; Wootten, D.; Lau, J.; Sexton, P. M.; Miller, L. J.; Ahn, J.-M.; Liao, J.; Fletcher, M. M.; Yang, D.; Brown, A. J. H.; Zhou, C.; Deng, J.; Wang, M. W. Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes. *Pharmacol. Rev.* **2016**, *68*, 954–1013.
- (41) García-Montero, A.; Rodríguez, A. M.; Juan, A.; Velders, A. H.; Denisi, A.; Jiménez-Osés, G.; Gómez-Bengoa, E.; Cativiela, C.; Gómez, M. V.; Urriolabeitia, E. P. Metal-Free [2 + 2]-Photocycloaddition of (Z)-4-Arylidene-5(4H)-Oxazolones as Straightforward Synthesis of 1,3-Diaminotruxillic Acid Precursors: Synthetic Scope and Mechanistic Studies. *ACS Sustainable Chem. Eng.* **2017**, *5*, 8370–8381.
- (42) Roiban, D.; Serrano, E.; Soler, T.; Grosu, I.; Cativiela, C.; Urriolabeitia, E. P. Unexpected [2 + 2] C-C bond coupling due to photocycloaddition on orthopalladated (Z)-2-aryl-4-arylidene-5(4H)-oxazolones. *Chem. Commun.* **2009**, 4681–4683.
- (43) Serrano, E.; Juan, A.; García-Montero, A.; Soler, T.; Jiménez-Marquez, F.; Cativiela, C.; Gómez, M. V.; Urriolabeitia, E. P. Stereoselective Synthesis of 1,3-Diaminotruxillic Acid Derivatives: An Advantageous Combination of C-H-ortho-Palladation and On-Flow [2 + 2]-Photocycloaddition in Microreactors. *Chem. - Eur. J.* **2016**, *22*, 144–152.
- (44) Carrera, C.; Denisi, A.; Cativiela, C.; Urriolabeitia, E. P. Functionalized 1,3-Diaminotruxillic Acids by Pd-Mediated C-H Activation and [2 + 2]-Photocycloaddition of 5(4H)-Oxazolones. *Eur. J. Inorg. Chem.* **2019**, *2019*, 3481–3489.
- (45) Urriolabeitia, E. P.; Sánchez, P.; Pop, A.; Silvestru, C.; Laga, E.; Jiménez, A. I.; Cativiela, C. Synthesis of esters of diaminotruxillic bis-amino acids by Pd-mediated photocycloaddition of analogs of the Kaede protein chromophore. *Beilstein J. Org. Chem.* **2020**, *16*, 1111–1123.
- (46) Filler, R.; Rao, Y. S. New Aspects of the Chemistry of 5-Thiazolones. *J. Org. Chem.* **1962**, *27*, 3730–3731.
- (47) Barrett, G. C. The Chemistry of 1,3-Thiazolinone \rightleftharpoons Hydroxy-1,3-Thiazole Systems. *Tetrahedron* **1980**, *36*, 2023–2058.
- (48) Feng, M.; Tang, B.; Liang, S. H.; Jiang, X. Sulfur-Containing Scaffolds in Drugs: Synthesis and Application in Medicinal Chemistry. *Curr. Top. Med. Chem.* **2016**, *16*, 1200–1216.
- (49) Scott, K. A.; Njardarson, J. T. Analysis of US FDA-Approved Drugs Containing Sulfur Atoms. *Top. Curr. Chem.* **2018**, *376*, 5–34.
- (50) Clarke, H. T.; Johnson, J. R.; Robinson, R. In *Chemistry of Penicillin*; Clarke, H. T., Ed.; Princeton University Press: New Jersey, 2016.
- (51) Thiazole and Its Derivatives: Part 1. In *The Chemistry of Heterocyclic Compounds*; Metzger, J. V., Ed.; John Wiley & Sons: New York, 1979; Vol. 34.
- (52) El-Naggar, A. M.; Eissa, I. H.; Belal, A.; El-Sayed, A. A. Design, Eco-Friendly Synthesis, Molecular Modeling and Anticancer Evaluation of Thiazol-5(4H)-Ones as Potential Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site. *RSC Adv.* **2020**, *10*, 2791–2811.
- (53) Lewis, F. D.; Howard, D. K.; Oxman, J. D. Lewis Acid Catalysis of Coumarin Photodimerization. *J. Am. Chem. Soc.* **1983**, *105*, 3344–3345.
- (54) Lewis, F. D.; Oxman, J. D.; Gibson, L. L.; Hampsch, H. L.; Quillen, S. L. Lewis Acid Catalysis of Photochemical Reactions. 4. Selective Isomerization of Cinnamic Esters. *J. Am. Chem. Soc.* **1986**, *108*, 3005–3015.

- (55) Lewis, F. D.; Quillen, S. L.; Hale, P. D.; Oxman, J. D. Lewis Acid Catalysis of Photochemical Reactions. 7. Photodimerization and Cross-Cycloaddition of Cinnamic Esters. *J. Am. Chem. Soc.* **1988**, *110*, 1261–1267.
- (56) Lewis, F. D.; Barancyk, S. V. Lewis Acid Catalysis of Photochemical Reactions. 8. Photodimerization and Cross-Cycloaddition of Coumarin. *J. Am. Chem. Soc.* **1989**, *111*, 8653–8661.
- (57) Lewis, F. D.; Elbert, J. E.; Uthagrove, A. L.; Hale, P. D. Lewis Acid Catalysis of Photochemical Reactions. 9. Structure and Photoisomerization of (*E*)- and (*Z*)-Cinnamamides and Their Lewis Acid Complexes. *J. Org. Chem.* **1991**, *56*, 553–561.
- (58) Lewis, F. D.; Oxman, J. D.; Huffman, J. C. Photodimerization of Lewis Acid Complexes of Cinnamate Esters in Solution and the Solid State. *J. Am. Chem. Soc.* **1984**, *106*, 466–468.
- (59) Brimiouille, R.; Guo, H.; Bach, T. Enantioselective Intramolecular [2 + 2] Photocycloaddition Reactions of 4-Substituted Coumarins Catalyzed by a Chiral Lewis Acid. *Chem. - Eur. J.* **2012**, *18*, 7552–7560.
- (60) Yoon, T. P. Photochemical Stereocontrol Using Tandem Photoredox-Chiral Lewis Acid Catalysis. *Acc. Chem. Res.* **2016**, *49*, 2307–2315.
- (61) Daub, M. E.; Jung, H.; Lee, B. J.; Won, J.; Baik, M.-H.; Yoon, T. P. Enantioselective [2 + 2] Cycloadditions of Cinnamate Esters: Generalizing Lewis Acid Catalysis of Triplet Energy Transfer. *J. Am. Chem. Soc.* **2019**, *141*, 9543–9547.
- (62) Poplata, S.; Bauer, A.; Storch, G.; Bach, T. Intramolecular [2 + 2] Photocycloaddition of Cyclic Enones: Selectivity Control by Lewis Acids and Mechanistic Implications. *Chem. - Eur. J.* **2019**, *25*, 8135–8148.
- (63) Behringer, H.; Stein, H. W. Über die Umsetzung von Azlactonen mit Thiosäuren. (Vorläufige Mitteilung). *Chem. Ber.* **1949**, *82*, 209–212.
- (64) Behringer, H.; Jepson, J. B. Notiz zur Reaktion von Azlactonen mit Thiosäuren. *Chem. Ber.* **1952**, *85*, 138.
- (65) Coutouli-Argyropoulou, E.; Thessalonikeos, E. Reactions of nitrile oxides and nitrile imines with 4-arylidene-2-phenyl-5(4*H*)-thiazolones. *Liebigs Ann. Chem.* **1990**, *1990*, 1097–1100.
- (66) Chandrasekhar, S.; Srimannarayana, M. The Erlenmeyer synthesis with a thioazlactone. *ARKIVOC* **2009**, *12*, 290–295.
- (67) Stoermer, R.; Bachér, F. Über die Konfiguration der Truxin- und Truxillsäuren (VI). *Ber. Dtsch. Chem. Ges. B* **1922**, *55*, 1860–1882.
- (68) Stoermer, R.; Bachér, F. Zur Stereoisomerie der Truxillsäuren und über die Auffindung der letzten Säure dieser Gruppe (VIII). *Ber. Dtsch. Chem. Ges. B* **1924**, *57*, 15–23.
- (69) Runcevski, T.; Blanco-Lomas, M.; Marazzi, M.; Cejuela, M.; Sampedro, D.; Dinnebier, R. E. Following a Photoinduced Reconstructive Phase Transformation and its Influence on the Crystal Integrity: Powder Diffraction and Theoretical Study. *Angew. Chem., Int. Ed.* **2014**, *53*, 6738–6742.
- (70) Liang, S.; Liu, S.-X.; Jin, H.-Z.; Shan, L.; Yu, S.-C.; Shen, Y.-H.; Li, H.-L.; Wu, Q.-Y.; Zhang, W.-D.; Sun, Q.-Y. Two novel innovanoside dimers from *Daphne aurantiaca* and a concise total synthesis of diinnovanoside A. *Chem. Commun.* **2013**, *49*, 6968–6970.
- (71) Wheeler, K. A.; Wiseman, J. D.; Grove, R. C. Enantiocontrolled solid-state photodimerizations via a chiral sulfonamide-cinnamic acid. *CrystEngComm* **2011**, *13*, 3134–3137.
- (72) Grove, R. C.; Malehorn, S. H.; Breen, M. E.; Wheeler, K. A. A photoreactive crystalline quasiracemate. *Chem. Commun.* **2010**, *46*, 7322–7324.
- (73) Gnanaguru, K.; Ramasubbu, N.; Venkatesan, K.; Ramamurthy, V. A study on the photochemical dimerization of coumarins in the solid state. *J. Org. Chem.* **1985**, *50*, 2337–2346.
- (74) Allen, F. H.; Kennard, O.; Watson, D. G.; Brammer, L.; Orpen, A. G.; Taylor, R. Tables of bond lengths determined by X-ray and neutron diffraction. Part 1. Bond lengths in organic compounds. *J. Chem. Soc., Perkin Trans. 2* **1987**, *S1*–S19.
- (75) Cleary, T.; Brice, J.; Kennedy, N.; Chávez, F. One-pot process to *Z*- α -benzoylamino-acrylic acid methyl esters via potassium phosphate-catalyzed Erlenmeyer reaction. *Tetrahedron Lett.* **2010**, *51*, 625.
- (76) Lee, S.-H.; Yoon, J.; Nakamura, K.; Lee, Y.-S. Efficient Syntheses and Ring-Opening Reactions of *trans*- and *cis*-Oxazoline-5-carboxylates. *Org. Lett.* **2000**, *2*, 1243–1246.
- (77) Nitz, T. J.; Lindsey, J.; Stammer, C. H. An excursion into the synthesis of potential angiotensin converting enzyme inhibitors. *J. Org. Chem.* **1982**, *47*, 4029–4032.
- (78) Gaumont, A.-C.; Gulea, M.; Levillain, J. Overview of the chemistry of 2-thiazolines. *Chem. Rev.* **2009**, *109*, 1371–1401.
- (79) Alsharif, Z. A.; Alam, M. A. Modular synthesis of thiazoline and thiazole derivatives by using a cascade protocol. *RSC Adv.* **2017**, *7*, 32647–32651.
- (80) Mollo, M. C.; Bisceglia, J. A.; Kilimciler, N. B.; Mancinelli, M.; Orelli, L. R. Microwave-Assisted Synthesis of 2-Substituted 2-Thiazolines and 5,6-Dihydro-4*H*-1,3-thiazines. *Synthesis* **2020**, *52*, 1666–1679.
- (81) You, S.-L.; Razavi, H.; Kelly, J. W. A Biomimetic Synthesis of Thiazolines Using Hexaphenylphosphonium Trifluoromethanesulfonate. *Angew. Chem., Int. Ed.* **2003**, *42*, 83–85.
- (82) Liu, J.; Wen, Y.; He, F.; Gao, L.; Gao, L.; Wang, J.; Wang, X.; Zhang, Y.; Hu, L. Ruthenium(II)-catalyzed C-O/C-S cyclization for the synthesis of 5-membered O-containing and S-containing heterocycles. *Org. Chem. Front.* **2019**, *6*, 846–851.
- (83) Bengtsson, C.; Nelander, H.; Almqvist, F. Asymmetric Synthesis of 2,4,5-Trisubstituted Δ^2 -Thiazolines. *Chem. - Eur. J.* **2013**, *19*, 9916–9922.
- (84) Dunbar, K. L.; Scharf, D. H.; Litomska, A.; Hertweck, C. Enzymatic Carbon-Sulfur Bond Formation in Natural Product Biosynthesis. *Chem. Rev.* **2017**, *117*, 5521–5577.
- (85) Vorbrüggen, H.; Krolikiewicz, K. A simple synthesis of Δ^2 -oxazines, Δ^2 -oxazines, Δ^2 -thiazolines and 2-substituted benzoxazoles. *Tetrahedron* **1993**, *49*, 9353–9372.
- (86) Charette, A. B.; Chua, P. Mild Method for the Synthesis of Thiazolines from Secondary and Tertiary Amides. *J. Org. Chem.* **1998**, *63*, 908–909.
- (87) Lemercier, B. C.; Pierce, J. G. Synthesis of Thiazolines by Copper Catalyzed Aminobromination of Thiohydroxamic Acids. *Org. Lett.* **2014**, *16*, 2074–2076.
- (88) Liu, B.; Davis, R.; Joshi, B.; Reynolds, D. W. Phosphine-Catalyzed Annulation of Thioamides and 2-Alkynoates: A New Synthesis of Thiazolines. *J. Org. Chem.* **2002**, *67*, 4595–4598.
- (89) Raman, P.; Razavi, H.; Kelly, J. W. Titanium(IV)-Mediated Tandem Deprotection-Cyclodehydration of Protected Cysteine *N*-Amides: Biomimetic Syntheses of Thiazoline- and Thiazole-Containing Heterocycles. *Org. Lett.* **2000**, *2*, 3289–3292.
- (90) Cook, A. H.; Harris, G.; Heilbron, S. Studies in theazole series. Part V. A synthesis of β -phenylcysteine. *J. Chem. Soc.* **1948**, 1060–1065.
- (91) Doyle, F. P.; Holland, D. O.; Mamalis, P.; Norman, A. Thiazolidines. Part V. Synthesis of β -alkylcysteines. *J. Chem. Soc.* **1958**, 4605–4614.
- (92) Holland, D. O.; Mamalis, P. Thiazolidines. Part IV. Further Reactions of 2-Methylthio-5-phenylthiazoline-4-carboxylic Acid. *J. Chem. Soc.* **1958**, 4601–4605.
- (93) Kim, T.-S.; Lee, Y.-J.; Jeong, B.-S.; Park, H.; Jew, S. Enantioselective Synthesis of (*R*)- and (*S*)-Alkylcysteines via Phase-Transfer Catalytic Alkylation. *J. Org. Chem.* **2006**, *71*, 8276–8278.
- (94) Vanderhaeghe, H.; Thomis, J. Preparation and Properties of 5-Phenylphenoxymethylpenicillin. *J. Med. Chem.* **1975**, *18*, 486–490.
- (95) Adams, A.; De Kimpe, N. Chemistry of 2-Acetyl-1-pyrroline, 6-Acetyl-1,2,3,4-tetrahydropyridine, 2-Acetyl-2-thiazoline, and 5-Acetyl-2,3-dihydro-4*H*-thiazine: Extraordinary Maillard Flavor Compounds. *Chem. Rev.* **2006**, *106*, 2299–2319.
- (96) McKeever, B.; Pattenden, G. Total synthesis of trunkamide A, a novel thiazoline-based prenylated cyclopeptide metabolite from *Lissoclinum* sp. *Tetrahedron* **2003**, *59*, 2713–2727.

(97) Schmidt, E. W.; Nelson, J. T.; Rasko, D. A.; Sudek, S.; Eisen, J. A.; Haygood, M. G.; Ravel, J. Patellamide A and C biosynthesis by a microcin-like pathway in *Prochloron didemni*, the cyanobacterial symbiont of *Lissoclinum patella*. *Proc. Natl. Acad. Sci. U. S. A.* **2005**, *102*, 7315–7320.

(98) Miura, C.; Kiyama, M.; Iwano, S.; Ito, K.; Obata, R.; Hirano, T.; Maki, S.; Niwa, H. Synthesis and luminescence properties of biphenyl-type firefly luciferin analogs with a new, near-infrared light-emitting bioluminophore. *Tetrahedron* **2013**, *69*, 9726–9734.

(99) Wipf, P.; Reeves, J. T.; Day, B. W. Chemistry and Biology of Curacin A. *Curr. Pharm. Des.* **2004**, *10*, 1417–1437.

(100) Havrylyuk, D.; Roman, O.; Lesyk, R. Synthetic approaches, structure activity relationship and biological applications for pharmacologically attractive pyrazole-pyrazoline-thiazolidine-based hybrids. *Eur. J. Med. Chem.* **2016**, *113*, 145–166.

(101) Tan, F.; Shi, B.; Li, J.; Wu, W.; Zhang, J. Design and Synthesis of New 2-Aryl-4,5-dihydro-thiazole Analogues: In Vitro Antibacterial Activities and Preliminary Mechanism of Action. *Molecules* **2015**, *20*, 20118–20130.

(102) Jin, Z. Muscarine, imidazole, oxazole and thiazole alkaloids. *Nat. Prod. Rep.* **2009**, *26*, 382–445.

(103) Huang, Y.; Gan, H.; Li, S.; Xu, J.; Wu, X.; Yao, H. Oxidation of 4-carboxylate thiazolines to 4-carboxylate thiazoles by molecular oxygen. *Tetrahedron Lett.* **2010**, *51*, 1751–1753.

(104) Plöchl, J. Ueber Phenylglycidssäure (Phenylloxacrylsäure). *Ber. Dtsch. Chem. Ges.* **1883**, *16*, 2815; *Ber. Dtsch. Chem. Ges.* **1884**, *17*, 1616.

(105) Erlenmeyer, E. Ueber die Condensation der Hippursäure mit Phtalsäureanhydrid und mit Benzaldehyd. *Justus Liebigs Annalen der Chemie* **1893**, *275*, 1.

(106) Carter, H. E. Azlactones, Chapter 5 of the book series. *Organic Reactions* **2004**, *3*, 198.

(107) Filler, R. *Adv. Heterocycl. Chem.*; Katrizky, A. R., Ed.; Academic Press: New York, 1954; Chapter 4, p 75.

(108) Rao, Y. S.; Filler, R. Geometric Isomers of 2-Aryl(Aralkyl)-4-arylidene(alkylidene)-5(4H)-oxazolones. *Synthesis* **1975**, *12*, 749.

(109) Rao, Y. S.; Filler, R. Oxazolones. In *Chem. Heterocycl. Compd.*; Turchi, I. J., Ed.; John Wiley & Sons: New York, 1986; Vol. 45, pp 361.

(110) Cativiela, C.; Díaz de Villegas, M. D.; Meléndez, E. On the synthesis of geometric isomers of 2-methyl (or phenyl)-4-[α -arylethylidene]-5(4H)-oxazolones. *J. Heterocycl. Chem.* **1985**, *22*, 1655.

(111) Bautista, F. M.; Campelo, J. M.; García, A.; Luna, D.; Marinas, J. M.; Romero, A. A. Study on dry-media microwave azalactone synthesis on different supported KF catalysts: influence of textural and acid-base properties of supports. *J. Chem. Soc., Perkin Trans 2* **2002**, 227.

(112) Roiban, G-D.; Soler, T.; Contel, M.; Grosu, I.; Cativiela, C.; Urriolabeitia, E. P. Reactivity of Unsaturated 5(4H)-Oxazolones with Hg(II) Acetate: Synthesis of Methyl N-Benzoylamino-3-arylacrylates. *Synth. Commun.* **2012**, *42*, 195–203.

(113) Mesaik, M. A.; Rahat, S.; Khan, K. M.; Ullah, Z.; Choudary, M. I.; Murad, S.; Ismail, Z.; Rahman, A. U.; Ahmad, A. Synthesis and immunomodulatory properties of selected oxazolone derivatives. *Bioorg. Med. Chem.* **2004**, *12*, 2049.

(114) *CrysAlis RED*, version 1.171.27p8; Oxford Diffraction Ltd.: Oxford, 2005.

(115) *SAINT Software Reference Manuals*, Version 5.0; Bruker Analytical Xray Systems, Inc.: Madison, WI, 2000.

(116) Sheldrick, G. M. *SADABS, Program for absorption and other corrections*; Göttingen University, 1996.

(117) Sheldrick, G. M. SHELXS-86, Phase annealing in SHELX-90: direct methods for larger structures. *Acta Crystallogr., Sect. A: Found. Crystallogr.* **1990**, *A46*, 467.

(118) Sheldrick, G. M. SHELXL-97, A short history of SHELX. *Acta Crystallogr., Sect. A: Found. Crystallogr.* **2008**, *A64*, 112.